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"There is one malady which I have in five cases
seen with what appeared to be enlargement of the
heart This malady to which I allude is
enlargement of the thyroid gland,"
Caleb Hillier "Parry 1786.
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ABSTRACT
Cardiovascular function and autonomic activity have been
investigated in hyperthyroid, hypothyroid and euthyroid
subjects with varying degrees of thyroid hormone
abnormality.
Twelve out of 90 patients (13%) presenting to a cardiology
clinic with apparently idiopathic atrial fibrillation were
demonstrated to have occult hyperthyroidism with suppression
of the pituitary-thyroid axis. Sinus rhythm was
reestablished after specific antithyroid therapy in 7 out of
8 patients with thyroid hormone concentrations outwith the
normal range and in all 4 patients in whom concurrent
illness or drug therapy had normalised hormone levels.
Clinically occult hyperthyroidism is a treatable cause of
"idiopathic" atrial fibrillation in a significant proportion
of patients and can be identified consistently only with the
thyrotrophin-releasing hormone test. Isolated suppression of
the pituitary-thyroid axis was achieved by thyroxine feeding
in 7 normal subjects and was associated with a significant
nocturnal and daytime tachycardia and reductions in the
ratio of daysnight urinary flow and sodium excretion,
compared to the same subjects as controls. Important
abnormalities in target organ function therefore occur with
changes in peripheral hormone concentrations within the
normal range.
Isovolumetric and ejection phase indices of left
ventricular contractile function have been investigated
using isotope ventriculography and echophonocardiography at
rest and on exercise in 24 hyperthyroid and 8 hypothyroid
subjects before and after corrective therapy. Left
ventricular ejection fraction (LVEF) and velocity of
circumferential fibre shortening (Vcf) are increased in
hyperthyroidism at rest with a reduced pre-ejection period
(PEP) but LVEF and Vcf fall significantly during dynamic and
static exercise to a level significantly less than occurs in
the same patients euthyroid for at least 3 months. LVEF is
reduced in hypothyroid patients but responses to exercise
are maintained. Directional changes in contractility were
not influenced by autonomic blockade. Sequential analysis of
myocardial contractility during antithyroid therapy showed
that normalisation of responses to exercise could be delayed
for many weeks after a biochemical euthyroid state had been
achieved. It is hypothesised that myocardial contractile
function is depressed in both hyper- and hypothyroidism and
that the hyperthyroid responses at rest reflect the
peripheral actions of thyroid hormone excess.
Analysis of heart rate and blood pressure responses on
exercise and over 24 hours in 10 hyperthyroid and matched
euthyroid subjects before and during beta-adrenoceptor
blockade showed parallel variations in these parameters
independent of activation of the cardiac neurosympathetic
axis. These findings support the concept that thyroid
hormone-sympathetic interactions are additive and not
synergistic and that adrenergic hypersensitivity does not
occur in clinical hyperthyroidism.
Paracetamol pharmacokinetics have been analysed in 7
hyperthyroid and 4 hypothyroid subjects before and after
corrective therapy. The substantial differences in
absorption and metabolism of this compound in these states
highlights the importance of changes in systemic autonomic





Disorders of thyroid function have been recognised to
involve the cardiovascular system for almost two hundred
years. Indeed, the first account of a patient with
hyperthyroidism described a cardiovascular manifestation
(Parry, 1786) that in retrospect suggested atrial
fibrillation preceeding by some years the classical
endocrine manifestations of the disease. The close
relationship between thyroid disease and the heart has
been well documented for over fifty years (Levine and
Sturgis, 1924) and many of the clinical descriptions of
this period are still valid. Some of the cardiovascular
manifestations of hyperthyroidism and hypothyroidism are
among the most characteristic abnormalities found in these
conditions.
Despite the recognition of the haemodynamic
alterations that occur with differing thyroid function,
the precise mechanism or mechanisms reponsible for these
changes have not been adequately identified. The
similarities between the effects of excess thyroid
hormones and stimulation of the sympathetic nervous system
suggested some thyroid-sympathetic interrelationship
(Brewster, 1956). An adrenergic contribution to the
clinical manifestations of hyperthyroidism was first
suggested by the finding that sympathetic blockade
produced by injection of procaine into the subarachnoid
space could successfully relieve or prevent hyperthyroid
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crisis (Knight, 1945). The successful use of
sympatholytic agents such as reserpine (Canary et al,
1957) guanethidine (Waldstein et al, 1966) and more
recently beta-adrenoceptor blocking drugs (Howitt and
Rowlands 1966; Shanks et al, 1969; Toft et al, 1978) in
controlling some of the peripheral manifestations of
hyperthyroidism has further strengthened this view.
These drugs reduce tachycardia, pulse pressure, cardiac
output and oxygen consumption towards normal in
hyperthyroid patients.
Thyroid Hormone-Sympathetic Nervous System Interactions
Tyrosine is the parent amino acid to both
catecholamine neurotransmitters and the thyroid hormones
thyroxine (T4) and triiodothyronine (T3) (figure 1.1).
It is therefore not surprising that catecholamines and
thyroid hormones have synergistic actions on a range of
metabolic processes. Theoretically thyroid-sympathetic
interactions can occur at several sites.
Fluorescence histochemical techniques have shown
fairly dense adrenergic innervation of the thyroid gland
in experimental animals (Melander et al, 1974a, 1975a) and
in man (Melander et al, 1974b, 1975b). Electrical
stimulation of sympathetic nerves, drug-induced release of
noradrenaline and direct administration of catecholamines
can all induce secretion of thyroid hormones (Melander et
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alf 1974a, 1976). It is likely, however, that this pathway
is a means of rapid but transient alteration in thyroid
hormone secretion in response to certain stimuli rather
than a vehicle for the sustained changes in hormone
production characteristic of thyroid gland dysfunction.
Release of neurotransmitter from sympathetic nerve
terminals may be modified by thyroid hormone actions on
central neuro-sympathetic outflow, presynaptic control of
catecholamine release or re-uptake, or metabolism and
removal mechanisms after catecholamine release. Each of
these mechanisms would result in increased or decreased
noradrenaline concentrations at the adrenergic nerve
terminal and consequently increased or decreased post¬
synaptic adrenoceptor activation.
Alternatively, thyroid hormones may alter target cell
sensitivity to released catecholamines. Such an
adaptation can arise from a primary change in adrenoceptor
density and or binding affinity to the target cell, or
alteration of intracellular readout systems such as
adeny1-cyclase activation and cyclic adenosine
monophosphate (cAMP) production.
Finally, thyroid hormones may act independently but
in parallel with the sympathoadrenal system resulting in a
biologically similar response through a quite separate
mechanism. Apparent sympathoadrenal overactivity in
hyperthyroidism would result from summation of the effects
of sympathetic activity and excess thyroid hormones.
Removal of either contribution to the overall biological
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FIGURE 1.1 Biosynthesis of catecholamines and thyroid
hormones; tyrosine is the parent amino

























response by sympatholytic or antithyroid agents would
alleviate some but not all of the clinical manifestations
of the disease.
There is no direct evidence that the sympathetic
nervous system or adrenal medulla are overactive in
hyperthyroidism. Myocardial noradrenaline turnover is
either normal (Beaven et al, 1963) or reduced (Beley et
alr 1973) in experimental hyperthyroid animals with no
change in the activity of catechol-o-raethyl transferase or
monoamine oxidase (Wurtman et alf 1963). Urinary
noradrenaline and adrenaline excretion is similarly normal
or low in hyperthyroid patients (Wiswell et alf 1963;
Bayliss and Edwards, 1971; Coulombe et al, 1976). Plasma
levels of noradrenaline are either low or normal
(Christensen, 1973; Stoffer et alr 1974) and levels of
dopamine beta-hydroxylase, a marker of neuronal
catecholamine release, are reduced (Nishizawa et al, 1974;
Noth and Saulding, 1974).
In contrast, experimental thyroid deficiency
increases cardiac noradrenaline turnover suggesting
increased sympathetic neural activity (Landsberg and
Axelrod, 1968). Urinary noradrenaline excretion is normal
or increased in hypothyroid patients (Wiswell et al, 1963;
Bayliss and Edwards, 1971) and plasma noradrenaline and
dopamine beta-hydroxylase levels are increased
(Christensen, 1973; Stoffer et al, 1973; Ghione et al,
1974; Nishizawa et al, 1974).
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Available evidence thus suggests normal or depressed
sympathetic activity in hyperthyroidism and some increase
in activity in hypothyroidism. Is it therefore unlikely
that thyroid hormone augmentation of neuro-sympathetic
outflow can explain the circulatory manifestations of
hyperthyroidism. Plasma and urinary catecholamines aref
however, an indirect assessment of the functional activity
of adrenergic nerve terminals. Direct turnover data in
patients is lacking.
Many early experimental studies suggested that both
chronotropic and pressor responses to exogenous
catecholamines were potentiated in hyperthyroidism
(Harrison, 1964). However, these studies did not measure
reponses over a variety of catecholamine concentrations
and therefore target cell hypersensitivity cannot be
assumed. More recent data in a variety of experimental
hyperthyroid animals have defined dose-response
relationships to catecholamine infusions and sympathetic
nerve stimulation and failed to show evidence of
cardiovascular adrenergic hypersensitivity (Buccino et al,
1967; Cairoli and Crout, 1967; Levey et al, 1969; Anton
and Gravestein, 1970; Brus et al, 1970; Turner and
Shenfield, 1980). Isolated tissue studies, however, have
not shown uniform agreement. Wildenthal (1972, 1974)
showed that isolated foetal mouse hearts exposed to T3 in
organ culture became more sensitive to the chronotropic
effects of beta-adrenoceptor stimulation. The
interpretation of these studies remains difficult because
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hearts in organ culture are effectively denervated and
depleted of endogenous catecholamines. Denervation
hypersensitivity might thus be expected. Several
investigators have shown increased rat myocardial
phosphorylase A activation by catecholamines in
hyperthyroidism (Hornbrook et al, 1965? McNeil and Brodie
1968; Hornbrook and Cabral, 1972).
Changes in cardiovascular sensitivity to
catecholamines have been studied much less frequently in
man. Early studies again suggested adrenergic
hypersensitivity in hyperthyroidism with potentiated
catecholamine effects on heart rate and blood pressure
that returned to normal after antithyroid treatment
(Schneckloth et alr 1953? Murray and Kelley, 1959). More
recent studies in hyperthyroid and hypothyroid patients
have documented changes in inotropic and chronotropic
responses during graded catecholamine infusion (Amidi et
al, 1968? Grossman et alf 1971). Although chronotropic
responses were shown to be mediated partly through the
beta-adrenoceptor, myocardial contractility in thyroid
dysfunction appeared to be independent of neuro-
sympathetic activity as responses were not substantially
altered by catecholamine depletion using reserpine or by
beta-adrenoceptor blockade with sotalol. Detailed
haemodynamic studies by Aoki et al (1967) in healthy
volunteers before and during T3 feeding failed to show an
augmented haemodynamic response to graded infusions of
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adrenaline and noradrenaline. Although resting heart rate
and cardiac index were increased 41 per cent and 56 per
cent respectively by T3, with a 39 per cent fall in
peripheral vascular resistance, the increments in these
parameters with adrenaline infusions (from 0.04 to 0.30
ug/kg/min) were similar in both euthyroid and hyperthyroid
states. More recently, McDevitt et al (1978) have examined
heart rate responses to graded infusions of isoprenaline
in hyperthyroid, hypothyroid and euthyroid subjects. No
shifts in the dose-response curves were detectable with
differing thyroid function.
Over the past few years, radioligand-binding methods
have been developed for the direct study of receptors and
these have been successfully applied to adrenergic
receptors (Maguire et al, 1977). Binding of high specific
activity iodine 125 and tritium labelled beta-adrenoceptor
antagonists to cardiac tissue is saturable, reversible and
stereospecific (Lefkowitz, 1975). Adrenergic receptors are
subject to regulation both by hormones or agonists that
normally interact with these receptors ("homologous") and
by influences such as other types of hormones or drugs
that do not normally interact with the receptor
("heterologous").
Thyroid status has been shown to alter both alpha-
and beta-adrenoceptor binding characteristics in cardiac
tissue. Banerjee and Kung (1977), Ciaraldi and Marinetti
(1977) and Williams et al (1977) all noted an increase in
beta-adrenoceptor numbers in experimental hyperthyroidism
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with no change in binding affinity. In contrast, cardiac
alpha-adrenoceptor binding declined in hyperthyroidism and
increased in hypothyroidism ( Fregly et alf 1975; Ciaraldi
and Marinetti, 1977; Sharma and Banerjee, 1978a; Williams
and Lefkowitz, 1979 ). Other membrane components such as
sialic acid content, Na-K adenosine triphosphatase
(ATPase) and Ca-K-ATPase activities were unchanged in the
hearts from hyperthyroid animals (McConnaughey et al,
1979). It has been suggested that the changes in
adrenergic sensitivity may represent a thyroid hormone
induced allosteric change in a single adrenergic receptor
(Kunos et al, 1974). Alternatively, thyroid hormones may
induce de novo synthesis of new beta-adrenoceptors or may
induce insertion or activation of preformed beta-
adrenoceptors (Kempson et al, 1978) into the cell
membrane. Thyroid disorders are one of several
pathophysiological states that change adrenoceptor density
or binding affinity (Lefkowitz, 1979). Receptor' regulation
may thus be an important mechanism controlling tissue
sensitivity to drug and hormone action. An increase in
beta-adrenoceptor density, provided such receptors remain
physiologically active, implies increased tissue
responsiveness or sensitivity to catecholamines
irrespective of whether the maximum biological response is
achieved with complete or incomplete receptor occupation.
As indicated above, there has been no clear physiological
evidence of alteration of catecholamine sensitivity in
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vivo with differing thyroid function. As radioligand
binding techniques progress, molecular and biochemical
aspects of autonomic receptors are recognised as being
increasingly complex (Watanabe et al, 1982). Subcellular
distribution of adrenoceptors in myocardial cells (Jones
et al, 1978, 1979; Misselwitz et al, 1979) or the ratio of
high to low affinity agonist binding sites on the
sarcolemma (Kent et al, 1980; Hoffman and Lefkowitz, 1980)
may be important determinants of an apparent change in
total receptor density. Thus, an assessment of the
functional significance of a change in adrenoceptors is an
important element before firm conclusions can be drawn.
An alternative explanation of a change in
catecholamine sensitivity involving beta-adrenoceptors has
been suggested by Malbon et al, (1978) to explain the
lipolytic response to adrenaline from normal, hypothyroid
and hyperthyroid rats. Although there was no detectable
difference in the number of beta-adrenoceptors obtained
from these fat cells, the catecholamine-stimulated adenyl-
cyclase activity, as measured by the accumulation of
cyclic adenosine monophosphate (cAMP), varied directly
with thyroid status. Tissue lipolysis, estimated by
glycerol release, was proportional to cAMP accumulation.
Thus thyroid hormones may modulate the amplification of
the beta-adrenoceptor signal at the level of the cell
membrane by regulating receptor-adeny1 cyclase
interactions. Whether such a mechanism operates in the
myocardium is unknown, although Levey and Epstein (1969)
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have suggested activation of myocardial adenyl cyclase in
vitro by thyroid hormones.
Direct Cardiac Effects of Thyroid Hormones
Direct effects of thyroid hormones on the heart were
demonstrated by Markowitz and Yater in 1932. Thyroxine
added to heart fragments of chick embryos that were devoid
of functioning adrenergic tissue caused a significant
increase in the beating rate of these cells after twelve
hours of hormone exposure. Thyroxine also enhanced the
rate of contraction of isolated guinea-pig atrium even in
the presence of adrenergic blockade (Murayama and
Goodkind, 1968). Antiadrenergic agents have been shown to
decrease the tachycardia of hyperthyroidism, but the heart
rate does not return to control levels (Cairoli and Crout,
1967). Right ventricular papillary muscles from
experimental hyper thyroid cats showed increased
contractility as reflected by an upward shift in the
myocardial force-velocity curve with increased velocity of
myocardial fibre shortening. Time to p?qk tension during
isometric contraction was reduced with augmented peak
tension development (Buccino et al, 1967). Non-invasive
indices of ventricular function derived from systolic time
intervals showed no major changes in hyperthyroid patients
following beta-adrenoceptor blockade (Grossman et al,
1971).
15
The tachycardia of hyperthyroidism is probably
secondary to direct thyroid hormone effects on the
sinoatrial node. There is an increased rate of diastolic
depolarisation and shortened action potential duration in
these cells that persists in the presence of propranolol
(Johnson et al,1973). The increased risk of development of
arrhythmias in hyperthyroidism, particularly atrial
fibrillation, may relate to a shortened refractory period
and reduced electrical stimulation threshold in atrial
cells in experimental hyperthyroidism (Arnsdorf and
Childers, 1970). Changes in ventricular refractoriness in
hyperthyroidism are reflected by reduction of the
corrected QT interval (Sandler, 1959; Hoffman and Lowry,
1960). Interatrial conduction disturbances, manifest by
abnormal P wave morphology or prolongation of the PR
interval on the surface electrocardiogram, occur in 15 and
5 per cent of hyperthyroid patients respectively.
Intraventricular conduction disturbances, most commonly
right bundle branch block, occur in about 15 per cent of
hyperthyroid patients in the absence of associated heart
disease (Benker et al, 1974). The cause of the
atrioventricular conduction disturbances is not clear
since animal experiments have shown shortening of the
functional refractory period of the conduction system in
hyperthyroidism and reciprocal changes in hypothyroidism
(Goel et al, 1972). These electrocardiographic
abnormalities may reflect a true thyroid cardiomyopathy
(Sandler and Wilson, 1959; Staffurth and Morrison, 1968),
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an aspect discussed further in chapters 4 and 5.
As thyroid hormones affect many tissues and stimulate
a variety of biochemical processes, the question arises as
to whether all of the observed effects are the consequence
of the induction of a common cellular event, or whether
they represent different responses elicited by the hormone
at several cellular levels (Bernal and Refetoff, 1977).
Furthermore, the concentration of thyroid hormones needed
to elicit a response in vitro is usually far in excess of
the concentration operative in vivo (Goldfine et al,
1975). Dosage may be particularly important in
experimental studies as some thyroid hormone effects are
biphasic, being stimulatory at low doses and inhibitory at
high doses (Hoch 1974; Vonderhaar, 1975). Several
mechanisms of action of thyroid hormone have been
suggested (Sterling, 1979) and these are summarised
diagrammatically for the heart in figure 1.2. Thyroid
hormone stimulation of protein synthesis has been
demonstrated in whole animals as well as cultured cells
(Kurtz et al, 1976; Martial et al, 1977; Shapiro et al,
1978). The effect involves increased transcription of DNA
information and increased RNA polymerase activity (Tata
and Widnell, 1966), possibly through association of the
thyroid hormone-receptor complex with nucleolar chromatin
(Gardner, 1975). Thyroid hormones also stimulate the
cell membrane enzyme, sodium-potassium ATPase (the sodium
pump) and may induce local changes in cardiac membrane
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FIGURE 1.2 Theoretical model for thyroid hormone action
on a cardiac muscle cell (diagrammatic).
Events are probably similar for T4 and T3.
The unbound hormone (circled) diffuses or is
transported into the cell and is bound by
cytoplasmic binding proteins (CBP). This
T3-CBP complex is in reversible equilibrium
with intracellular unbound T3 that can
interact with binding proteins of the
effector loci on the cell nucleus,
mitochondria or sarcolemma, as shown. The
dominant effects on myocytes appear to be
mediated through alteration of nuclear








phospholipids (Philipson and Edelman, 1977). Since
approximately 40 per cent of the oxygen consumption in
many normal mammalian tissues, including the myocardium,
appears to be dependent on membrane sodium transport, this
may be an important final pathway of energy expenditure in
response to thyroid hormones (Edelman, 1974). This
effect is more likely to be due to an increased number of
pump units than alteration of pre-existing enzyme
molecules (Lo et al., 1976; Lo and Edelman, 1976), and
hence may be secondary to stimulation of nuclear
transcription, rather than a primary effect on enzyme
activity. Red cell sodium concentration has been
suggested as a sensitive index of peripheral thyroid
hormone action in hyperthyroidism with increases up to 50
per cent from the euthyroid state (Goolden et al, 1971).
Thyroid hormones can increase the synthesis of cardiac
myosin and alter its structure (possibly by the appearance
of a new myosin isoenzyme) increasing its intrinsic
contractile properties (Thyrum et al., 1970; Yazaki and
Raben, 1975; Banerjee et al., 1976). Augmented myosin
ATPase activity and/or augmented actin-activation of
myosin ATPase may contribute to the enhanced contractile
response of the hyperthyroid heart (Banerjee and Morkin,
1977), since the activity of this enzyme is thought to
regulate the turnover of actin-myosin cross-bridge links
in cardiac muscle (Morkin 1979). Sarcoplasmic reticulum
from hyperthyroid animals also accumulates and exchanges
calcium at an increased rate resulting in increased
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availability of calcium to the myofibrils during
activation as well as an enhanced rate of myofibrillar
relaxation (Nayler et al., 1971; Suko, 1973). The role
of thyroid hormones in altering adrenergic receptor
density on target cell membranes has already been briefly
discussed.
Although it is unlikely that alteration of protein
synthesis per se can account for all of the observed
changes in cell function with thyroid hormones, this
mechanism may be fundamental to several of the changes in
myocardial function in thyroid disease.
The mitochondrion has been considered a possible
subcellular locus of thyroid hormone action for many years
in view of the crucial role of mitochondria in energy
metabolism. High affinity saturable binding of thyroid
hormones to mitochondrial membranes has been demonstrated
(Sterling and Milch, 1975; Sterling et al., 1978), similar
to that reported previously for the cell nucleus (Degroot
and Torresani, 1975; Macleod and Baxter 1976). This
specific receptor is a macromolecule arising from the
inner mitochondrial membrane, which is known to be the
site of oxidative phosphorylation (Lehninger, 1975). The
precise manner in which hormone binding to this receptor
site might enhance oxidative phosphorylation is unknown.
The effect is, however, independent of the cell nucleus as
it can be demonstrated in isolated mitochondrial
preparations (Sterling, 1977). Increased mitochondrial
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ATP production has been observed as early as 30 minutes
after the intravenous injection of triiodothyronine to
hypothyroid rats. Increased ATP production persists
despite blockade of protein synthesis with cycloheximide
(Sterling et al., 1977).
An intriguing hypothesis for the mechanism of action
of thyroid hormones has proposed that they function as
amino acid analogues of tyrosine (Dratman, 1974).
Thyroxine and triiodothyronine (halogen-substituted
aromatic amino acid analogues) can be incorporated into
protein fractions and accelerate protein degradation with
secondary stimulation of protein synthesis and turnover.
As triiodothyronine is concentrated in peripheral
adrenergic nerves and localised and metabolised within
synaptosomes (Dratman et al., 1976), it is conceivable
that iodothyronines may enter into catecholamine
biosynthetic pathways and act as precursors for alternate
adrenergic neurotransmitters.
It is most likely that multiple cellular mechanisms
and an integrated response underly the effects of thyroid
hormones on the myocardium (figure 1.2). The relative
importance of the various mechanisms discussed is,
however, unknown.
Systemic Autonomic Activity and Thyroid Disease
Some of the cardiovascular effects of thyroid disease
are manifest by alteration in specific organ function.
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This has important implications for rational drug
prescribing in the management of thyroid dysfunction and
its cardiovascular complications. Changes in regional
blood flow (Degroot and Leonard, 1970) for example may
result in altered drug disposition by influencing the rate
and extent of drug absorption, speed of onset and
magnitude of drug effect and drug distribution and
elimination. These proc esses are further modified by
primary disturbances of gastrointestinal motility
(Holdsworth and Besser, 1968; Thomas et al, 1973; Javitt,
1978) and alteration of hepatic drug metabolising enzyme
activity (Pitot and Yatvin, 1973).
Hypermotility of the small and large bowel has been
demonstrated in hyperthyroidism by both radiographic
techniques (Javitt, 1978) and study of bowel electrical
activity (Christensen et al, 1964; 1966). Gut motility
disturbances may be major features of thyroid hormone
deficiency (Bacharach and Evans, 1957; Baker and Harvey,
1971) and in advanced cases may be associated with colonic
enlargement, paralytic ileus and serous effusions (Kocen
and Atkinson, 1963; Boruchow et al, 1966) .
The metabolism and excretion of many drugs are
accelerated in hyperthyroidism. Maintainance therapy with
0.5mg oral digoxin daily has been shown to result in
substantially lower plasma digoxin levels in hyperthyroid
than hypothyroid patients (mean levels of 0.9 and 1.9 nmol
per litre respectively) with a reduced plasma digoxin half
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life in the former group. The reduction probably reflects
both an increased glomerular filtration rate and increased
rate of digoxin metabolism in the hyperthyroid
patients (Croxon and Ibbertson, 1975). Thus, persisting
tachycardia in some patients with hyperthyroidism and
atrial fibrillation despite standard maintainance digoxin
dosage may be due to inadequate plasma digoxin
concentrations in addition to impaired digoxin-induced
slowing of atrioventricular conduction. Significant
differences in the pharmacokinetics of propranolol and
practolol after oral dosage have also been shown in
hyperthyroid and hypothyroid subjects (Bell et al, 1977).
Purpose of Thesis
This thesis documents several aspects of
cardiovascular function in hyperthyroid, hypothyroid and
euthyroid subjects. Where possible, control studies have
been repeated on the same patient when euthyroid after
specific treatment to avoid some of the problems of inter-
patient variability and allow comparison of paired data.
Chapter 2 investigates an aspect of cardiovascular
function in hyperthyroidism, atrial fibrillation, that
highlights the prevalence of this abnormality in patients
with relatively minor disturbances of plasma thyroid
hormone concentrations and underlines the value of the
plasma thyrotrophin (TSH) response to thyrotrophin
releasing hormone (TRH) in routine diagnosis. Clinical
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evidence is presented for a reassessment of the threshold
for antithyroid therapy in patients with atrial
fibrillation and isolated suppression of the pituitary-
thyroid axis and this is supported in chapter 3 by
abnormalities in cardiovascular function in normal
subjects on physiological thyroxine replacement with
similar pituitary-thyroid axis suppression.
Chapters 4 and 5 identify abnormalities in left
ventricular function in thyroid disease and responses to
corrective therapy using two non-invasive techniques,
namely isotope ventriculography and combined
echocardiography and systolic time interval measurements.
Analyses have been performed at rest and during dynamic
and isometric exercise before and during autonomic
blockade. Left ventricular contractile performance under
stress may be impaired in hyperthyroidism, in direct
contrast to the commonly held view, and both the extent
and time-course of this impairment and its relationship to
autonomic influences have been examined.
The studies presented in chapter 6 have been designed
principally to assess whether there is a change in
adrenergic sensitivity in hyperthyroidism. In view of the
importance of neural mechanisms in cardiovascular control,
responses to exercise and beta-adrenoceptor blockade have
been used in preference to systemic catecholamine
infusions.
Finally, in chapter 7, the extent and magnitude of
24




disturbances are assessed by
paracetamol absorption,
in patients with differing
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CHAPTER 2
'Idiopathic* atrial fibrillation and occult
hyperthyroidism: the functional significance of isolated
suppression of the pituitary-thyroid axis.
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Overt hyperthyroidism has been recognised as a cause
of atrial fibrillation for many years (Goodall, 1920;
Wilson, 1924; Nahum and Hoff, 1935) and accounted for 14
percent of cases in an early series (Campbell, 1947).
Despite being one of the most frequent disorders of
cardiac rhythm, the electrophysiological mechanism of
atrial fibrillation remains uncertain (Abildskov et al,
1971). Although spontaneous reversion to sinus rhythm
may be expected in approximately two thirds of patients
after antithyroid treatment (Teoh et al, 1974; Nakazawa
et al, 1980), some, particularly the elderly, require
cardioversion to sinus rhythm when euthyroid (Symons,
1979; Nakazawa et al, 1980).
The most striking electrophysiological abnormality in
experimental hyperthyroidism is a reduction in the
duration of the action potential recorded from individual
atrial cells associated with an increased rate of
diastolic depolarisation (Freedberg et al, 1970; Johnson
et al, 1973). In contrast, action potential duration is
prolonged in hypothyroidism (Freedberg et al, 1970). A
reduction in action potential duration increases the
electrical excitability of the atrium, evidenced by a
reduction in stimulation threshold for a given coupling
interval (Arnsdorf and Childers, 1970), and thus increases
any tendency to develop fibrillation. These data are
supported by clinical studies suggesting that the duration
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of the monophasic action potential, a technique for
recording depolarisation and repolarisation phenomena in
cardiac muscle in situf is an important predictor of
recurrent atrial fibrillation after cardioversion (Olson
et al, 1971? Cotoi et al, 1972). Monophasic action
potential duration correlates fairly closely with direct
recordings from studies using intracellular electrodes
(Hoffman et al, 1959). Patients with a persistently
short monophasic action potential duration following the
re-establishment of sinus rhythm have a higher incidence
of recurrent atrial fibrillation than those in whom it is
normal (Cotoi et alf 1972).
The early diagnostic tests for hyperthyroidism were
relatively crude and in many instances the diagnosis
rested primarily on clinical grounds. With the advent of
sophisticated tests of thryoid function, an accurate
biochemical diagnosis can be made independent of clinical
findings.
This study was undertaken to identify the incidence
of hyperthyroidism in a selected population of consecutive
patients referred to a cardiology clinic for paroxysmal or
persistent atrial fibrillation in whom the diagnosis of
hyperthyroidism was not made by the referring practitioner
or with confidence by the consulting cardiologist.
Methods
Ninety consecutive patients (58 men and 32 women)
28
with an age of 59 + /- 12 years (mean +/- standard
deviation) were studied. They were referred to the
Department of Cardiology over an eighteen month period
between August 1977 and January 1979 with sustained atrial
fibrillation that could not be satisfactorily explained on
the basis of known cardiovascular disease. This
population was selected from a total of approximately 350
patients with atrial fibrillation seen over this period.
In each of the 90 patients, atrial fibrillation was
confirmed by a routine electrocardiogram or by ambulatory
outpatient electrocardiographic monitoring. The
arrhythmia was considered to be 'idiopathic' in 65
patients and an unexpected development in the natural
history of an established cardiac disease in 25 patients.
The possible cardiovascular causes of atrial fibrillation
in these patients are summarised in table 2.1. Mitral
stenosis was excluded, where appropriate, by single
element echocardiography. A clinical diagnosis of
hyperthyroidism was considered in two patients each of
whom had slight diffuse thyroid gland enlargement.
In each of the 90 patients, blood was withdrawn for
the estimation of serum total thyroxine (T4),
triiodothyronine (T3) and thyrotrophin (TSH) level before
and 20 minutes after the intravenous administration of 200
ug of thyrotrophin -releasing hormone (TRH) (Synder and
Utiger, 1972; Hershman, 1974). In an attempt to exclude
abnormal concentrations of thyroid hormone binding
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proteins, the effective thyroxine ratio (ETR, Malinckrodt
(UK) ltd) was also measured (Thorson et al, 1972). Serum
total T4 and T3 were measured by specific
radioimmunoassays (Seth et al, 1976), where the interassay
precision level using anonymous control sera averaged 7.9
per cent for T3 and 11.7 per cent for T4, expressed as the
coefficient of variation. Serum TSH was also measured by
radioimmunassay in which the between assay coefficient of
variation was 11.2 per cent (Irvine et al, 1973). The
normal laboratory reference range for serum total T3 was
1.1 to 2.8 nanomoles/litre and for serum total T4 60 to
150 nanomoles/litre. The normal range for serum total
TSH was less then 0.7 to 5.7 milliUnits per litre and the
normal range of response 20 minutes after the intravenous
administration of 200 ug of TRH was 3.9 to 25.3
milliUnits/litre (Toft et al, 1978).
For the purposes of this study the diagnosis of
hyperthyroidism was made not on clinical grounds but on
the basis of lack of a serum TSH response to intravenous
TRH with or without raised levels of serum total T3 or T4.
Lack of response was defined as a failure of the 20 minute
level of TSH to increase by more than 0.5 milliUnits/litre
above the basal level.
A thyroid scan was performed in 11 of the 12






suspected angina of effort 4 2
previous myocardial infarction 3 2
Hypertension 1 1
Congenital heart disease
persistent ductus arteriosus - l
divided ductus arteriosus - l
mild pulmonary valve stenosis 1 l
aortic valve prosthesis 1,1*
Rheumatic heart disease
trivial mitral stenosis - l
mild aortic regurgitation 1
Other
mild mitral regurgitation - l*
alcoholic cardiomyopathy 2
previous viral myocarditis 1*
Total 15 10
* patients with biochemical hyperthyroidism
TABLE 2.1 Possible cardiovascular causes of atrial




An absent serum TSH response to intravenous TRH was
documented in 12 of the 90 patients (13 per cent), five
women and seven men, including three with associated heart
disease in the form of aortic and mitral valve lesions and
previous viral myocarditis respectively (table 2.1).
The age, sex, levels of serum total T4 and T3, serum
TSH responses to TRH, thryoid scan appearances, the
treatment and the cardiac rhythm qfter antithyroid therapy
in the eight patients with thyroid hormone concentrations
outwith the normal range are shown in table 2.2. With
the exception of cases one and seven, thyroid hormone
levels were only modestly elevated. The highest serum
total T4 was recorded in case seven, where the dominant
clinical feature was extreme apathy. This patient died
suddenly from a presumed cerebral embolus 10 days after
hospital admission. Atrial fibrillation persisted during
this period. In seven of the eight patients, stable
sinus rhythm was re-established after antithyroid
treatment, five spontaneously and two after elective DC
cardioversion. Sinus rhythm has persisted in these seven
patients over a 15-38 month follow-up period. In all of
them, serum total T3 and T4 and the TSH response to TRH
were normal at the time of or during the weeks preceeding
the re-establishment of sinus rhythm.
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CASE AGE(YR) SERUM TOTAL SERUM TSH(mU/l) THYROID Rx RHYTHM AFTER
NO & SEX T3 T4 RESPONSE TO TRH SCAN TREATMENT
(nmol/1) basal 20min
1 58F 5.4 242 1.1 1.2 normal 1131 spont SR at
2 months
2 51M 3.0 127 0.9 1.2 aut 1131 spont SR at
nodule 3 months
3 51M 4.5 188 1.7 2.0 aut 1131 CV to SR
nodule 6 months
4 73M 4.3 193 1.2 1.0 normal 1131 spont SR at
3 months
5 76M 2.8 162 1.0 <0.7 - CARB spont SR at
1 month
6 47M 4.1 190 <0.9 <0.9 normal 1131 spont SR at
1 month
7 65M 3.8 312 <0.7 <0.7 normal CARB death from
cerebral emb
at 10 days
8 70F 3.7 192 1.0 1.0 normal 1131 CV to SR
8 months
SR sinus rhythm; CV cardioverted; CARB carbimazole
TABLE 2.2 Age, sex, serum total T3 and T4 levels, TRH test,
thyroid scan results, treatment and eventual
cardiac rhythm in the eight patients- with
hyperthyroidism and elevated thyroid hormone
concentrations.
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Four patients (33 per cent) showed an absent TSH
response to TRH but serum total thryoid hormone
concentrations within the normal laboratory reference
range (table 2.3). On the basis of the lack of TSH
response to TRH, specific antithyroid therapy was
instituted. One patient (no. 10) reverted spontaneously
to sinus rhythm after six weeks and the other three were
successfully cardioverted to sinus rhythm between six and
nine months after starting antithyroid therapy. At the
time of return to sinus rhythm, serum thyroid hormones had
fallen significantly although still within the normal
range, and intravenous TRH produced a normal rise in
plasma TSH at 20 minutes (table 2.4). Direct current
cardioversion (maximum 400 joules) had been unsuccessful
in three patients (nos. 9,11 and 12) before specific
antithyroid therapy and had not been attempted in the
fourth (no. 10). Each patient merits brief clinical
description.
Case 9: A 46 year old woman was referred from
another hospital because of atrial fibrillation with an
uncontrolled ventricular rate associated with dyspnoea on
exertion. Tachycardia persisted despite therapeutic
serum digoxin levels and administration of oral
propranolol 10 mg every 8 hours. There were no clinical
or historical features of hyperthyroidism and no clinical,
radiographic or echocardiography evidence of mitral valve
disease. Serum total T4 levels had been repeatedly
normal along with serum total T3, the latter estimated for
the first time after the administration of propranolol
(table 2.3). Several attempts at DC cardioversion at a
maximum of 400 joules failed to establish sinus rhythm.
Because of the lack of serum TSH response to TRH and the
presence of a non-palpable autonomous thyroid nodule









ETR SERUM TSH(mU/l) THYROID
RESPONSE TO TRH SCAN
basal 20 min















TABLE 2.3 Age, sex, serum total T3 and T4 levels, ETR,
TRH test and thyroid scan results in the
four patients with isolated suppression of
the pituitary-thyroid axis.
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131 was administered. Nine months later DC cardioversion
was successful at 100 joules. Serum total T4 had
decreased from 102 to 97 nmol/1 and serum total T3 from
2.4 to 1.6 nmol/1 with a normal TSH response to TRH (table
2.4). It was assumed that the patient had a T3
hyperthyroidism associated with an autonomous thyroid
nodule but that the serum total T3 level was lowered by
administration of propranolol.
Case 10: A 67 year old woman had severe heart
failure and bilateral pleural effusions associated with
atrial fibrillation and an uncontrolled ventricular rate.
The tachycardia and heart failure responded to treatment
with bed rest and administration of digoxin and diuretic
agents. Propranolol therapy was not instituted because
of the presence of heart failure. Because of the lack of
serum TSH response to TRH (table 2.3), carbimazole was
added to the therapeutic regime. The atrial fibrillation
reverted to sinus rhythm six weeks later, when the serum
total T4 had fallen from 125 to 86 nmol/1 and serum total
T3 from 1.8 to 1.5 nmol/1 with a normal TSH response to
TRH (table 2.4). It was felt that this patient also had
a T3 hyperthyroidism and that the severity of the heart
failure resulted in a lowering of the serum T3 level.
Case 11: A 66 year old woman had documented atrial
fibrillation over a five year period. The ventricular
rate had always tended to be rapid, although this had been
partially controlled by digoxin and propranolol 40 mg
every 6 hours. Initial cardioversion (maximum 400
joules) was unsuccessful. Following the detection of an
absent TSH response to TRH (table 2.3), iodine-131 was
administered and the patient cardioverted to sinus rhythm
(50 joules) seven months later. Serum total T4 decreased
from 134 to 86 nmol/1 and serum total T3 from 2.2 to 1.4
nmol/1 at the time of successful cardioversion (table
2.4) .
Case 12: A 55 year old man developed persistent
atrial fibrillation six months after an acute febrile
illness diagnosed as a viral myocarditis, from which he
had apparently made a full recovery. An attempt at
cardioversion was unsuccessful and maintenance therapy
with digoxin and propranolol was continued. Full thyroid
function tests showed an absent TSH response to TRH and an
autonomous thryoid nodule detected by scintigraphy and
therefore iodine-131 was administered (table 2.3). Nine
months later, when serum total thryoid hormones had fallen










15mCi 1131 1.6 97 1.8 1.3
10 carblmazole 1.5 86 3.7 10.1
11 15mCi 1131 1.4 86 6.6
12 15mCi 1131 1.7 90 1.5 8.2
TABLE 2.4 Therapy, serum total T3 and T4 levels and
TRH test at time of conversion to sinus
rhythm.
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2.4), repeat cardioversion established sinus rhythm at 200
joules.
Stable sinus rhythm has persisted in two patients
(nos 10 and 11) over a follow-up of 28 and 36 months
respectively. One patient (no. 9) developed recurrent
atrial fibrillation 46 months after a period of persistent
sinus rhythm when serum total thyroid hormones and the
serum TSH response to TRH were normal. The fourth
patient (no. 12) re-developed atrial fibrillation four
months after successful cardioversion despite normal
thyroid function. As his resting electrocardiogram,
chest x-ray and echocardiogram showed some left atrial
enlargement, further cardioversion has not been attempted.
In each of the remaining 78 patients, there was a
normal serum total T3, T4 and TSH response to TRH.
Discussion
The physiological basis for atrial fibrillation has
not been conclusively established. Two general
electrophysiological mechanisms have been proposed;
firstly, the development of intrinsic pacemakers within
the atrium or automaticity (Scherf et al, 1953;
Prinzmetal et al, 1955) and secondly, reentry of atrial
excitation without continuing pacemaker function (Garrey,
1914). Experimental evidence suggests that while atrial
fibrillation can be induced by abnormal pacemaker
activity, it is maintained by the development of multiple
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reentrant circuits (Abildskov et al, 1971). Resting
diastolic transmembrane potentials in the sino-atrial node
may be reduced in experimental hyperthyroidism (Lenfant et
al, 1966) although this observation was not confirmed by
the studies of Freedberg et al (1970) performed at
constant heart rate. Any variability in recovery of
electrical excitation across the atrium will increase the
likelihood of development of fibrillation, a tendency that
may be enhanced by endogenous sympathetic tone. Vagal
stimulation produces a shortening of the atrial action
potential and refractory period in a non-uniform way.
Such electrical inhomogeneity could favour reentrant
excitation and atrial fibrillation (Alessi et al, 1958;
Moe and Abildskov, 1959; Langendorf et al, 1965).
Atrial fibrillation occurs in 10 percent of patients with
clinically overt hyperthyroidism (Sandler and Wilson,
1959). It has hitherto been considered an unusual cause
of atrial fibrillation in clinically euthyroid patients
(Symons et al, 1978). Although the role of
hyperthyroidism in precipitating atrial fibrillation in
the 12 patients described is not certain, it is likely to
be a cause and effect relationship because of the
reestablishment of stable sinus rhythm following
antithyroid therapy. These patients were elderly, with a
mean age of 60 years, and this may reflect both a
reduction in the threshold for atrial fibrillation with
age in the apparently normal heart (Campbell et al, 1974),
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possibly because of the relationship between atrial size
and the occurence and persistence of atrial fibrillation
(Moore et al, 1965), and an increase in the incidence of
occult ischaemic and degenerative heart disease (Kitchin
and Milne, 1977). In a study of 200 unselected
hyperthyroid patients, Summers and Surtees (1961) showed
that 30 percent had a cardiac abnormality and that the
incidence of coexisting heart disease increased with age.
In a Danish study of the prevalence of hyperthyroidism in
patients attending a county hospital (Ronnov-Jessen and
Kirkegaard, 1973), 25 per cent of patients with
hyperthyroidism who were over the age of 60 years had
atrial fibrillation with or without cardiac
decompensation. This contrasted with a 5 per cent
prevalence of atrial fibrillation in hyperthyroid patients
under the age of 60 years. It is well recognised that
atrial fibrillation is unusual in the young hyperthyroid
patient often despite markedly increased levels of thyroid
hormones. Diagnosis and treatment, however, are usually
undertaken promptly in this group, in contrast to the
elderly where the disease may have been undetected over
many years. A hypothetical scheme relating thyroid
hormone levels, age and atrial fibrillation in the younger
and older patient is shown in figure 2.1.
None of the patients presenting to the cardiology
clinic with atrial fibrillation was considered to be
hyperthyroid by the referring medical practitioner.
Furthermore, only two of the 12 patients ultimately found
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FIGURE 2.1 Schematic representation of the relationship
between thyroid hormones, age and atrial
fibrillation (AF) in the young and elderly
hyperthyroid patient. Early recognition and
treatment make AF unusual in the young
whereas late diagnosis with prolonged but
mild elevation of thyroid hormones, coupled
with the fall in AF threshold with age, make
this arrhythmia more common in the old.
Antithyroid therapy usually restores sinus
rhythm, but AF can recur at a later date
despite normal thyroid function.
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to be hyperthyroid on the basis of biochemical criteria
were suspected of having the disease by the consulting
cardiologist. It is well recognised that the typical
signs . . of hyperthyroidism may be absent in the older
patient where the course of the disease may be dominated
by heart failure and gastrointestinal symptoms (Ronnov-
Jessen and Kirkegaardf 1973). In some elderly patients
with hyperthyroidism, illustrated by case no. 7, the major
features are those of extreme apathy and weight loss
(Lahey, 1931; Thomas et alf 1970).
Measurement of a single thyroid hormone is clearly
not a sufficient screening test for hyperthyroidism in
patients with atrial fibrillation. If the measurement of
serum total T4 were the only thyroid function test
employed in patients with atrial fibrillation secondary to
T3-hyperthyroidism, the condition would remain undetected.
Indeed, this study has revealed an unexpectedly high
proportion of hyperthyroid patients with hyperfunctioning
solitary thyroid nodules (five out of 11 or 45 per cent).
It is well recognised that there is a high incidence of
preferential secretion of T3 by such 'hot* nodules
(Marsden et al, 1975). The association of an autononous
s
thyroid nodule with isolated suppres^on of the pituitary-
thyroid axis, present in three of the four patients in
this category, is also well recognised (Ridgway et al,
1973; Carpi et al, 1977) although it has been widely
assumed that these patients are 'euthyroid* and that
inhibition of the thyrotrophin-producing cells of the
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anterior pituitary, the thyrotrophs, reflects their unique
sensitivity to minor changes in circulating thyroid
hormones within the normal range. Untreated, however,
overt toxicity develops in approximately 10 percent of
these nodules over a one to six year follow-up (Hamberger,
1980).
Measurement of serum total T3 levels in isolation
would be equally unsatisfactory. Isolated elevation of
serum total T4 is a recognised clinical entity (Ahmad and
Cohen, 1981), present in 16 per cent of hyperthyroid
patients in a recent series (Caplan et al, 1980). It is
of interest that almost 50 per cent of these patients were
over 65 years of age. Most circulating T3 is derived
from the peripheral monodeiodination of T4. Non-
thyroidal illness, however, causes a reduction in serum
levels of active thyroid hormones and an increase in
concentration of the metabolically inactive isomer
'reverse* T3 (Burger et al, 1976). The rise in 'reverse*
T3 shows a close temporal relationship to the fall in T3,
reflecting either an alternative peripheral
monodeiodination of T4 to the inactive isomer (Burger et
al, 1976) or possibly decreased production of T3 and
removal of 'reverse' T3 from reduction in 5'deiodinase
enzyme activity (Kaplan and Utiger, 1978; Eisenstein et
al, 1978). Similar changes in peripheral thyroid hormone
metabolism can occur as a result of drug therapy with
propranolol (Harrower et al, 1977; Lotti et al,1977) or
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corticosteroids (Burr et al, 1976) although serum T3
levels tend to normalise after prolonged therapy
(Kristensen and Weeke, 1977). The fall in circulating
total T3 with propranolol is independent of initial
thyroid status (Wiersinga and Touber, 1977).
Thus, hyperthyroid patients with heart failure (no.
10) or those receiving propranolol (nos. 9,11,12). may have
serum total T3 levels within the normal range (Birkhauser
et al, 1977; Engler et al, 1978). Furthermore, serum
total T3 levels are lowered with increasing age in
healthy subjects over the age of 65 years (Rubenstein et
al, 1973), but normal reference ranges cited by
laboratories are usually based on levels found in healthy
young adults. Free thyroid hormone levels should mirror
thyroid status more accurately than total hormone levels
as it is this fraction that is metabolically active.
Although free hormone assays are becoming more widely
available, the commercial kits produce disparate results
in patients with non-thryoidal illness (Captein et al,
1981). In all forms of hyperthyroidism, there is a lack
of response of serum TSH to intravenous TRH, and this
response is unaffected by the previously described factors
influencing thyroid hormone levels. A lack of response
of TSH to TRH may occur in an apparently euthyroid patient
whose serum total T3 and T4 levels are abnormal for that
person but still within the accepted normal range (Snyder
and Utiger, 1972).
None of the eight patients with overt hyperthyroidism
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showed recurrence of atrial fibrillation when euthyroid.
However, two of the four patients with isolated pituitary-
thyroid axis suppression redeveloped atrial fibrillation
four and 46 months after successful cardioversion when
unequivocally euthyroid. It may be that these patients
continued to show reductions in atrial myocardial cell
action potential duration after antithyroid therapy and
hence a greater tendency to redevelop atrial fibrillation
(Olson et alf 1971), Alternatively, permanent structural
changes in the myocardium or a true thyroid cardiomyopathy
cannot be excluded. Although the duration of
hyperthyroidism in these four patients is not known, it is
probable that symptoms from atrial fibrillation had been
present for several years in at least three of the
patients, a factor that may have been relevant to any
structural abnormalities in the heart. Symons et al
(1971) demonstrated occult hyperthyroidism in eight
patients presenting with cardiovascular abnormalities;
four showed atrial fibrillation. Overt hyperthyroidism
developed in all of these patients with follow-up of up to
seven years although sinus rhythm was apparently achieved
in only one patient after anti-thyroid therapy.
Although the use of long-term anticoagulant agents in
patients with rheumatic heart disease and atrial
fibrillation is widely accepted (Rogers and Sherry, 1976),
anticoagulant therapy is less consistently administered to
patients with atrial fibrillation secondary to
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hyperthyroidism. Over an 18 year period, Staffurth et
al, (1977) treated 238 patients with hyperthyroidism and
atrial fibrillation and documented 26 episodes of arterial
embolism in 21 patients (nine per cent of the total).
The embolic events occurred during active hyperthyroidism
(12 events), on reversion to sinus rhythm (3 events) or
after the euthyoid state was established (11 events). In
a Scottish survey of in-patient hospital statistics
(Parker and Lawson, 1973) 31 deaths with a primary
diagnosis of hyperthyroidism were identified over a ten
year period. Atrial fibrillation was documented in 19
patients (61 per cent), the majority associated with heart
failure. Eight patients (26 per cent) presented with a
major arterial embolus. Based on these analyses, it is
now reasonable to anticoagulate all patients with atrial
fibrillation secondary to hyperthyroidism (intravenous
heparin followed by oral warfarin) unless specifically
contraindicated. Embolism is particularly prevalent in
the elderly and age should not in itself be a
contraindication to therapy (Forfar, 1978; 1982).
This study not only demonstrates that a significant
proportion of patients with apparently 'idiopathic* atrial
fibrillation have biochemical evidence of hyperthyroidism,
but also confirms that the diagnosis may be readily missed
in the older patient. Although the majority of such
patients will be detected with measurement of both serum
total T3 and T4 levels, the most reliable screening test
for hyperthyroidism is measurement of the serum TSH
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response to TRH. If this test is not performed, then a
significant proportion of patients with hyperthyroid
atrial fibrillation (in this study 33 per cent) will not
be identified. 'Idiopathic' atrial fibrillation is a
common clinical diagnosis and does not carry the benign
prognosis once suggested (Kannel et al, 1982). Minor but
inappropriate elevations of thyroid hormones in this
situation cannot be recognised without recourse to
assessment of the pituitary-thyroid axis by the TRH test.
It is important to recognise and treat this correctable
form of atral fibrillation in view of the haemodynamic
disturbances from loss of atrial systole and the rapid
ventricular rate (Morris et al, 1963; Gilbert et al,
1963), and the risks of systemic embolism associated with
this arrhythmia. Atrial fibrillation with an absent TSH
response to TRH should be considered sufficient grounds
for antithyroid therapy even if serum total T3 and T4 are
within the expected normal range.
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CHAPTER 3
Target Organ Function with Isolated Suppression of the
Pituitary-Thyroid Axis: is the Pituitary Thyrotroph
Uniquely Sensitive to Thyroid Hormones?
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The evidence presented in chapter 2 suggests that
important abnormalities in target organ function may be
triggered by minor increases in circulating thyroid
hormones within the normal range. This suggests that the
anterior pituitary may not be uniquely sensitive to small
increases in plasma total T3 and T4. With the more
widespread use of the TSH response to TRH in assessment of
adequacy of thyroxine replacement therapy (Jacksonr 1982),
it has been appreciated that the dose required for
hormonal replacement, based on preservation of the TSH
response to TRH, is substantially less than that
previously recommended (Evered et al, 1973; Stock et al,
1974; Maeda et al, 1976). Hoffman et al (1977) have
shown that a mean replacement dose of thyroxine of 172 +/-
53 ug per day is sufficient to cause TSH suppression in
patients with thyroid disorders where TSH suppressive
therapy is required. Interestingly, triiodothyronine
replacement therapy may be less effective in suppressing
pituitary TSH section than thyroxine (Erfurth and Hedner,
1982), possibly because of the higher capacity for
monodeiodination of thyroxine in the pituitary compared to
other tissues (Larson, 1982).
The administration of small quantities of thyroid
hormones to normal subjects, however, is known to impair
the TSH response to TRH without raising plasma total T3
and T4 above the normal range. Snyder and Utiger (1972)
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showed that administration of 15 ug triiodothyronine and
60 ug thyroxine daily over three weeks substantially
inhibited the TSH response to TRH. Braverman et al,
(1973) reported that administration of as little as 300 ug
thyroxine per day (which does not induce clinical
hyperthyroidism) to normal female subjects was associated
with increases in concentration of total and free T4 and
T3 and with a small increase in basal metabolic rate. It
is not known whether thyroid hormone therapy sufficient to
cause isolated suppression of the pituitary-thyroid axis
is associated with this state of "subclinical
hyperthyroidism" in normal subjects.
In order to investigate further the relationship
between thyroid hormones and target organ responses, this
study assessed changes in cardiac and renal function in
normal individuals administered thyroxine in a dose
sufficient to impair the TSH response to TRH without
increasing thyroid hormone levels into the hyperthyroid
range.
Methods
Seven normal subjects (6 men and 1 woman), aged 25 to
34 years agreed to take part in this study. None had
evidence of cardiac or renal disease and all had normal
resting ECG, plasma urea, electrolytes and negative
urinalysis. No subject received any drug therapy and all
took a normal unrestricted diet during the study period.
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Continuous 24 hour ambulatory ECG monitoring, day and
night urine collections for four consecutive 24 hour
periods and measurement of serum total T3, T4 and TSH
response to 200 ug TRH given intravenously were performed
under control conditions (when the TSH response to TRH was
normal) and during the 22nd - 26th days of oral thyroxine
administration (when the TSH response to TRH was
inhibited). Four subjects received thyroxine after and
three received thyroxine before the control period. The
dose of thyroxine was calculated from body weight such
that individuals less than 62.5 kg received 150 ug daily
and those over 62.5 kg 200 ug daily as a single dose. Two
subjects under 62.5 kg required the higher dose of
thyroxine to achieve complete TSH suppression; data
obtained at the lower dose of thyroxine was not included
in the analysis.
Heart rate was recorded continuously as an out¬
patient over 24 hours using an Oxford Medilog recording
system and a modified lead V5 chest electrode. Variations
in tape recorder speed were minimised by using the same
recorder for each subject and by incorporation of a fixed
frequency timing signal into the recorder (Department of
Medical Physics). Each recording was analysed at high
speed (Pathfinder II high speed ECG analyser, Reynolds
Medical) and R-R interval displayed continuously on a
Devices chart recorder. Maximum and minimum heart rates
(defined as the peak or trough rates over 30 seconds) and
mean heart rate (from the integral of the beat to beat R-R
interval) over each one hour recording period was
calculated. For the purposes of this analysis, day-time
was 0700-2300 hours and night-time 2300-0700 hours.
Separate containers were provided for day and night
urine collections. Subjects voided as required during
the day but were requested to empty their bladders
immediately before retiring at night and on rising in the
morning. After volume measurement, aliquots were
refrigerated at 4°C prior to analysis for sodium by flame
photometry (Bell et al, 1982a). The mean day/night (D:N)
ratios for urinary sodium excretion and flow were
calculated for each subject before and during thyroxine
administration (Dr Gordon Bell, Medical Renal Unit). The
night values related to night recumbancy while day values
related to the period between rising in the morning and
retiring in the evening. There was no difference in the
period of night recumbancy before or during the thyroxine
administration (8.4 +/- 1.2 hours and 8.5 +/- 1.1 hours
respectively).
Plasma total T3,T4 and TSH were measured by specific
radioimmunoassay (chapter 2). The normal range for total
T3 was 1.1 - 2.8 nanomoles/litre, for total T4 60-150
nanomoles/litre, and for TSH less than 0.7 to 5.7
milliUnits/litre. The normal range of response of TSH
20 minutes after the intravenous administration of 200 ug
of TRH was 3.9 to 25.3 milliUnits/litre.
Students 't' test for pair differences was used for
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BEFORE THYROXINE DURING THYROXINE
SUBJECT PLASMA TOTAL TSH(mU/l) PLASMA TOTAL TSH(mU/l)
T3 T4 RESPONSE TO TRH T3 T4 RESPONSE TO TRH
(nmol/1) basal 20min (nmol/1) basal 20min
1 2.0 93 2.9 13.8 1.8 141 <0.9 2.5
2 1.6 69 2.5 14.2 1.7 99 <0.9 1.1
3 1.4 96 2.0 9.9 1.4 136 <0.9 <0.9
4 1.5 87 2.3 20.0 2.4 120 <0.9 1.7
5 1.7 77 2.0 9.1 1.8 109 <0.9 2.9
6 1.9 116 4.1 12.2 2.1 146 <0.9 1.5
7 1.7 112 2.3 8.8 2.2 144 <0.9 1.2
MEAN 1.7 93 2.6 12.6 1.9 128 <0.9 1.7
+/-SEM +/-0.1 +/-6 +/-0.3 +/-1.5 +/-0.1 +/"7 - +/-0.3
TABLE 3.1 Plasma total thyroid hormones and the TSH
response to intravenous TRH before and during
thyroxine administration.
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Mean + SEM (upper panel) fmaximum and
minimum (lower panel) hourly heart
rates over each recording period in
the presence (closed circles) and
absence (open circles) of sufficient
oral thyroxine to cause isolated
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statistical analyses with a 5 per cent confidence limit
for statistical significance.
Results
The levels of the plasma total T4, T3 and TSH
responses to TRH before and during the 24th day of
thyroxine administration are shown in table 3.1. In each
case, thyroxine caused a small but significant (P<0.005)
rise in total T4, although well within the normal range,
and impaired the TSH response to TRH. Changes in total
T3 were minor and not statistically significant.
Mean, maximum and minimum heart rates during each
hour of the 24 hour recording are shown in figure 3.1.
Both the mean and minimum heart rates were consistently
faster during therapy compared to controls, with less
consistent increases in maximum heart rate. Figure 3.2
shows the average increases in day-time (0700-2300 hours)
and night-time (2300-0700 hours) mean, maximum and minimum
heart rates following thyroxine. It can be seen that
increases are consistently greater at night (7.1 +/- 0.7
beats/minute than during the day (3.1 +/- 0.6
beats/minute) but that at all times (except the maximum
day-time heart rate when changes were not statistically
significant), thyroxine administration has induced a
relative tachycardia.
Figure 3.3. shows the individual and mean values for
the D:N ratios of urinary flow and sodium excretion before
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and during days 22-26 of thyroxine administration.
Day:Night ratios of urinary flow and sodium excretion fell
significantly from 2.2 +/- 0.3 and 2.4 +/- 0.2 to 1.4 +/-
0.2 and 1.6 +/- 0.2 respectively with thyroxine (P<0.01).
These changes reflected a 21 per cent decrease in day-time
urine flow (from 78 +/- 12 to 60 +/- 12 ml/hour) and a 10
percent increase in nocturnal urine flow (from 43 +/- 8 to
47 +/- 5 ml/hour), associated with a 22 per cent decrease
in day-time sodium excretion (from 8.8 +/- 1.6 to 6.9 +/-
1.0 mmol/hour) and a 22 per cent increase in nocturnal
sodium excretion (from 3.8 +/- 0.6 to 4.6 +/- 0.7
mmol/hour).
Discussion
Normal thyroid hormone levels with an absent TSH
response to TRH have been documented in several
circumstances. It is a not uncommon finding in patients
who have been apparently successfully treated by
antithyroid drugs, radioiodine or subtotal thyroidectomy
(Clifton-Bligh et al, 1974; Buerklin et al, 1976, Irvine
and Toft, 1976; Toft et al, 1978) and has been described
in patients with non-toxic nodular goitre, ophthalmic
Graves' disease, autonomous thyroid nodules, euthyroid
subjects with a family history of Graves' disease and
patients receiving thyroxine replacement therapy (Lawton
et al, 1971; Ridgway et al, 1973; Carpi et al, 1977;
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FIGURE 3.2. Increments in day-time and night-time mean,
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Tamai et al, 1978). It is currently believed that the
pituitary thyrotroph in the most sensitive target organ
for thyroid hormones and is alone in recognising a state
of subclinical hyperthyroidism when these hormones
increase within the normal range. Subclinical
hyperthyroidism of this type has not hitherto been
considered an indication for antithyroid therapy although
it is recognised that some of these patients are at
increased risk of developing overt hyperthyroidism
(Hamberger et al 1980).
The present study suggests that both the heart and
the kidney are as responsive as the pituitary thyrotroph
to minor increases in circulating thyroid hormone levels
within the normal range. The changes in urine flow and
sodium excretion may be related to direct effects of
thyroid hormones on renal tubular membrane sodium exchange
(De Wardenerr 1978); alternatively, the increase in
nocturnal heart rate, which might be expected to be
combined with a small fall in peripheral vascular
resistance (Zaimis et al, 1969) may have led to an
increase in cardiac output and renal blood flow, with
consequent enhancement of nocturnal urinary flow and
sodium excretion. Increments in night-time heart rate
(and presumably cardiac output) after thyroxine were
greater than those during the day, reflecting lower
sympathetic tone at night and hence less overall
contribution to heart rate. This is probably also the
explanation for greater increases in minimum than in
FIGURE 3.3. Ratios of day-time (D) and night-time (N)
urinary flow and sodium excretion before
and during thyroxine administration
sufficient to cause isolated suppression of























maximum heart rates with thyroxine. Reversal or abolition
of the day:night pattern of urinary sodium excretion
occurs in overt hyperthyroidism (Bell et alr 1982a),
cardiac failure (Goldman 1951), the nephrotic syndrome and
chronic renal failure (Borst and DeVries, 1950; Hillier
et alf 1980). In these conditions, the relative increase
in nocturnal renal blood flow and glomerular
may be the explanation (Wesson, 1964).
Apart from the early weeks after surgical or radio-
iodine treatment of hyperthyroidism when there is a
transient suppression of pituitary thyrotrophs (Toft et
al, 1974), an impaired TSH response to TRH reflects
widespread target organ recognition of inappropriately
high levels of thyroid hormones, irrespective of whether
they lie within the accepted reference range. This stage
is subclinical only in as much as the physician is unable
to detect evidence on clinical grounds of the peripheral
manifestations of thyroid hormone excess. Thus, in the
absence of a carefully matched control group, Hoffman et
al (1977) cannot conclude that a noctural heart rate of 69
beats per minute (over 10 beats/min faster than in this
study) is normal in patients with TSH suppression. Indeed,
had Hoffman et al studied the same patients without TSH
suppression, it is highly likely that the nocturnal heart
rate would have been significantly lower. Whether the
cardiac and renal changes demonstrated are sufficient
evidence for a reassessment of the threshold for
antithyroid therapy depends upon proof that subclinical
60
hyperthyroidism is detrimental to the patient. The
patients with a cardiological diagnosis of 'idiopathic'
atrial fibrillation in whom there was biochemical
evidence of subclinical hyperthyroidism described in
chapter 2 could be restored to sinus rhythm after
appropriate antithyroid therapy (Forfar et al, 1981), thus
avoiding risks of systemic embolisation and heart failure.
Under certain circumstances, therefore, cardiotoxic
effects of minor increases in thyroid hormones are
evident. Abnormal left ventricular function in overt
hyperthyroidism is described in chapters 4 and 5 (Forfar
et al, 1982) and it is possible that similar cardiac
dysfunction may occur in patients with unrecognised
subclinical hyperthyroidism. Ridgway et al (1981), have
recently shown changes in myocardial contractile function
in patients with subclinical hypothyroidism (isolated
plasma TSH elevation) following thyroxine administration
although these authors did not exclude the possibility
that therapy induced subclinical hyperthyroidism as the
TSH response to TRH was not assessed. It has not been
established whether the alteration in the normal diurnal
pattern of sodium excretion may be a contributing factor
in some patients with unexplained oedema.
Just as hyperthyroidism is a graded phenomenon
(Evered et al, 1973; Tunbridge et al, 1977), there is a
spectrum of hyperthyroidism characterised in its early
stages by thyroid hormones within the accepted reference
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range but which are recognised by the pituitary, heart,
kidneys and presumably many other organs as
inappropriately high for the individual patient. This
stage of subclinical hyperthyroidism must have existed for
a variable period of time in all patients presenting with
overt hyperthyroidism. The evidence presented is
sufficient for a reassessment of the indications for
antithyroid therapy. It may also be necessary to assess
m
opti/um dosage of thyroxine replacement therapy more
accurately than at present by using the TSH response to




Left Ventricular Function in Hyper- and Hypothyroidism
Assessed by Radioisotope Ventriculography: Impaired
Contractile Performance with Thyroid Hormone Excess and
Deficiency.
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The mechanism of altered myocardial contractile
function in hyper- and hypothyroidism has been thesubject
of clinical and experimental investigation over several
decades. Most of the experimental studies in vitro have
documented enhanced myocardial contractility in
hyperthyroid states and depressed contractile function in
hypothyroid states (Buccino et al, 1967; Murayama and
Goodkind, 1968; Pannier,1968; Taylor et al, 1969).
However, in these and in other experimental studies with
an intact circulation,changes in thyroid status were
induced over a relatively short period oftime (a few
weeks) and therefore may not be strictly comparable to
spontaneous hyperthyroidism and hypothyroidism in humans.
A few studies have demonstrated reductions in
myocardial contractility with thyroid hormone feeding. In
rat papillary muscle, Korecky and Beznak (1971) recorded
small increases in rate of tension development and
shortened time to maximum tension, but noted that maximum
developed tension was unchanged. When thyroxine levels
were increased further, maximum tension decreased with a
further shortening in the time to peak tension. These
authors suggested that the response to thyroxine may have
been related to intrinsic heart rate. In species with
fast heart rates, the lowered turnover was the result of
failure of contraction velocity to increase in proportion
to the decrease in the duration of contraction. Taylor
(1970) confirmed the importance of contraction frequency
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on the inotropic effects of thyroxine on cat papillary
muscle. At low rates, indices of contractility (rate of
tension development, time to peak tension, peak tension,
velocity of isotonic shortening) were greater in papillary
muscles from hyperthyroid animals. With an increase in
/
contraction frequency from 12 to 60 beatsperminute,an
inotropic response was noted in hyperthyroid and euthyroid
groups but over the subsequent minutes, indices of
contractility decreased more rapidly in the hyperthyroid
muscles. This author attributed his results to a true
reduction in activity of the contractile muscle elements
from more profound hypoxia in hyperthyroid. muscles at high
contraction frequencies. There is no evidence that
hyperthyroidism alters series and parallel elastic and
viscous components in heart muscle (Buccino et al, 1967;
Parmley et al, 1968). Oxygen requirements of cardiac
muscle in vitro are substantially increased in
hyperthyroidism (Ullrick and Whitehorn, 1952). With an
intact circulation, sinus tachycardia or atrial
fibrillation with a rapid ventricular response may further
exacerbate hypoxia through increasing myocardial oxygen
demand and reducing diastolic coronary perfusion (Piatnek-
Leunissen and Olson, 1967). It has been estimated that
myocardial oxygen utilisation increases about 30 to 40 per
cent per unit mass of myocardium (which itself may be
increased) in the average hyperthyroid patient (Leight et
al, 1956; Rowe et al, 1956). Tse et al (1980) have
65
recently shown reductions of 40 per cent in ATP levels in
the hyperthroid rat heart, providing a biochemical basis
for the contractile responses observed. This ATP
depletion was no longer evident after regression of the
hyperthyroid state.
The mechanism of altered myocardial contractile
function in hypothyroidism has been less intensively
studied. Clinically, the bradycardia and cardiomegaly of
myxoedema are familiar (Fahr, 1932; Keating, 1961) and
experimentally, impaired myocardial contractility is well
documented (Buccino et al, 1966; Taylor et al, 1969;
Straver and Schulze, 1976). Similarly, the influence of
the sympathetic nervous system in maintaining myocardial
contractile function in states of thyroid hormone
deficiency is unknown. Although early studies suggested
that alterations in cardiac sensitivity to catecholamines
could not explain the hypodynamic circulatory state
characteristic of the condition (Benforado and Wiggins,
1965; Margolius and Gaffney, 1965), radioligand binding
studies (discussed in chapter 1 and chapter 6) have shown
that both beta- and alpha-adrenoceptor density is
decreased in ventricles from propylthiouracil-treated
rats, thus providing a mechanism for reduced adrenergic
sensitivity.
The purpose of this study was to examine left
ventricular contractile function and its response to
exercise and beta-adrenoceptor blockade in untreated
hyperthyroid and hypothyroid patients and in the same
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patients when euthyroid after appropriate anti-thyroid or
thyroxine replacement therapy. In the absence of major
changes in preload and afterload, left ventricular
ejection fraction (LVEF) reflects the intrinsic
contractile state of the heart. Radionuclide
ventriculography provides a sensitive and non-invasive
technique for assessment of ventricular function at rest
and on exercise.
Methods
A total of 17 patients agreed to participate in the
investigation. Nine were hyperthyroid (eight women and
one man: mean age 48 years [range 19-58 years]) and eight
hypothyroid ( all women: mean age 53 years [range 37-69
years] at the time of initial study.
The diagnosis of hyperthyroidism was made clinically
and on the basis of raised levels of plasma total
thyroxine (T4) and triiodothyronine (T3) associated with
an absent plasma thyrotrophin (TSH) response 20 minutes
after 200 ug thyrotrophin releasing hormone (TRH) given
intravenously (table 4.1). None of the patients were
receiving medication at the time of study; all were
clinically free from heart failure and had no evidence of
concurrent cardiovascular disease based on history,
clinical examination, electrocardiogram and chest




JHHENT WT T3 T4 HE test(mj/l) WT B ® Iffl SECY
& SEX (Kg) (nmcJ/1) basal 20min (Kg) (nmol/1) WOO (rrnth)
42F 32.3 35.0 382 <1.0 <1.0 48.5 13 94 1.7 10
44F 44.9 12.7 342 1.7 03 48.6 1.7 114 1.0 11
58F 40.7 5.3 207 <0.8 <D.8 42.5 1.5 74 1.0 6
19F 45.0 12.4 330 <03 <03
57F 45J. 4.7 201 0.9 0.8 53.0 1.4 69 6.8 6
57F 55.0 6.0 225 1.0 1.0 58.5 13 99 03 12
49F 60.5 7.2 218 1.1 1.1 62.0 1.9 75 3.1 8
8 54M 66.0 9.1 193 1.1 1.0 73.0 2.1 125 13 9
53F 473 6.8 240 <0.7 <0.7 54.6 1.9 308 2.0 9
TPBLE 4.1 Age at pcesatatim, sex, vei^nt and tigroid fircticn tests
at the tine cf angiografhic iiraestiqBticn in patisits vtei
l^perthyrcdd and euthyroid.
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diagnosis, investigation and treatment. Eight of the
nine patients were restudied when euthyroid after specific
antithyroid therapy (10-15 mCi radioiodine 1131 in
patients 1-3 and 5-9; subtotal thyroidectomy in patient
4) to allow paired data analysis. Studies were repeated a
minimum of six months and a maximum of 12 months after
antithyroid treatment. All patients had been
biochemically euthyroid for at least three months before
repeat investigation.
The diagnosis of hypothyroidism was made clinically
and on the basis of reduced levels of plasma T4 associated
with elevation of plasma TSH (table 4.2). No patients
were receiving medication at the time of the first
investigation. Seven had primary hypothyroidism and one
(patient 17) developed hypothyroidism following 15 mCi
radioiodine 1131 for hyperthyroidism four months
previously. One patient (no. 11) gave a history of mild
chest pain on exertion compatible with angina pectoris but
specific cardiac symptoms were absent in the remainder.
All were clinically free from heart failure at the time of
study. Cardiomegaly (CTR 55 per cent) was noted on
routine chest radiograph in patient 16. Seven of the
eight patients showed non-specific ST/T wave changes on
the resting electrocardiogram. Each patient was restudied
between four and eight months after thyroxine replacement
therapy when clinically and biochemically euthyroid (table




EKHENT PCS WT T4 TEH WT 14 TEH THVRTKTNF .cnny
(kg) (rmcJ/L) (ntyl) (kg) (rncQ/L) WD (ug/cfey) (nnth)
ID 46 55.0 <20 >85.0 50.9 88 3.9 150 5
H 57 65.0 35 51.7 61.5 116 33 150 8
12 59 125.0 <20 >85.0 105.0 120 3.6 150 8
13 37 81.0 28 633 80.0 78 33 100 5
14 59 69.6 26 74.0 64.7 90 3.0 150 4
15 50 67.4 <20 64.0 643 79 2.3 100 6
16 69 74.5 24 >81.0 75.8 83 2.6 150 4
17 44 49.6 <20 363 4B.6 114 1.7 100 5
UHE 4.2 £ge at presentation, weight and tigroid function at the time
of angiographic iiwesticpfcion in patia±s vtei l^poti^rcdd
and eud^roid.
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at least eight weeks before restudy. Chest pain on
exertion was transiently more frequent in patient 11 and
for this reason thyroxine replacement was increased
gradually over six months and combined with propranolol
and long-acting nitrates. Both of these drugs were
discontinued in this patient before repeat study.
Isotope ventriculography was performed in the supine
position with cardiac imaging in the 30 degree left
anterior oblique projection with 10 degrees caudal tilt
using either a Nuclear Enterprises Mark 5HR or a Searle
(LEM) mobile gamma camera (figure 4.1). Following an
intravenous bolus injection of 15 mCi of technetium 99m
electrolytically labelled human serum albumin (Millar et
alf 1979), praecordial counts were transferred and stored
in 20 msec frame format in a PDP 11/34 computer (Digital
Equipment Corporation). The accumulation was triggered by
c
the R wave of the patients ele(trocardiogram, recorded from
chest lead V5, each 20 msec frame being updated by
successive cardiac cycles until 300-500 beats had been
accumulated. At the end of the accumulation period, the
frames were displayed in rapid sequence or movie format on
a purpose built display screen. The provisional
ventricular outline was selected from the display using a
joy-stick and data from within this outline displayed to
produce the uncorrected ventricular volume curve. the
ventricular region displayed could be checked and where
necessary altered by displaying the volume curves from
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FIGURE 4.1 Gamma camera positioned in 30 degree left




individual picture-cell elements. Background subtraction
was made from a crescentic shell of the lateral and
inferior ventricular border corrected to provide an area
equal to the left, ventricle and the LVEF was calculated
from this corrected time-activity curve (Muir et al,
1977). Left ventricular wall motion was examined from
the continuous movie display.
A further index of ventricular function was
calculated as the mean ejection time (TS), expressed as a
proportion of left ventricular ejection time (LVET). The
mean ejection time was defined by:
y- (Vi - Vi + 1).(ti + ti + 1)
i 2
TS = — msecs
21 (Vi - Vi + 1)
i
where Vi is the relative ventricular volume at time ti
during systole. Ts was therefore derived from the sum of
the products of successive volume changes and the average
time between these frames. LVET was taken to be the time
during which greater than 98 per cent of the total volume
change during systole took place. The TS : LVET ratio is
therefore a measure of the shape of the volume curve
during systole (Muir et al, 1980); if a greater
proportion of the volume empties in early systole then the
ratio will be reduced. Regional myocardial fibre
shortening and the ratio should thus correlate closely
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(and inversely) to the intrinsic contractile state of the
heart.
Patients rested for 15 minutes before the start of
each study. Ventricular volume curves were constructed
over 500 beats at rest and over 300-500 beats during
supine exercise on a bicycle ergometer. The work rate was
adjusted for each patient between 300-600 kpm/minute and
exercise continued for two to three minutes before
initiating data accumulation. This time was sufficient to
achieve steady state in hyperthyroid, hypothyroid and
euthyroid groups, assessed by a constant heart rate (+/- 5
per cent) during the data accumulation period. After a
further 30 minute rest period, propranolol 0.15 mg/kg (ICI
Pharmaceuticals, England) was given by intravenous
injection over five minutes and the same protocol repeated
after a further 15 minutes. Systolic blood pressure was
measured by the same observer (JCF) using a mercury
sphygmomanometer at rest and on exercise before and after
propranolol. The same protocol at the same work loads
was used for each patient at restudy when euthyroid.
Thyroid function tests were undertaken before each
study as described in chapter 2. The normal range for
plasma total T4 is 60 to 150 nmol/1, for plasma total T3
1.1 to 2.8 nmol/1, and for plasma TSH less than 0.7 to 5.7
mU/1 with the normal range of response 20 minutes after
the intravenous administration of 200 ug TRH 3.9 to 25.3
mU/1.
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FIGURE 4.2 LVEF at rest and on exercise in the same
patients hyperthyroid and euthyroid before
(closed symbols) and after (open symbols)
propranolol. LVEF falls on exercise when
hyperthyroid before and after beta-
adrenoceptor blockade in contrast to a rise
on exercise when euthyroid.
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Statistical analysis used the Wilcoxon ranked sura
and signed-rank two-tailed test for matched pairs and two
samples. Correlations between thyroid hormone
concentrations, LVEF and heart rate used a linear
regression co-efficient with least squares method of
analysis and computed t-statistic.
Results
The resting LVEF was significantly (10 per cent)
greater when hyperthyroid compared to the same patients
when euthyroid (figure 4.2). Mean (+/- SEM) resting LVEF
hyperthyroid was 0.58 +/- 0.03 compared to 0.53 +/- 0.02
euthyroid (P < 0.02). On exercise, LVEF decreased in
eight of the nine hyperthyroid patients and was unchanged
in the remaining patient (LVEF on exercise 0.55 +/- 0.02:
P < 0.01 compared to resting LVEF). In contrast, LVEF
increased in seven out of the eight patients when
euthyroid and fell slightly in the eighth patient. LVEF
on exercise (euthyroid) was 0.61 +/- 0.03 (P < 0.01
compared to resting LVEF). The LVEF on exercise when
hyperthyroid was significantly less (P < 0.02) than when
euthyroid.
Directional and absolute changes in LVEF when
hypothyroid were different to those in the hyperthyroid
state. Resting LVEF was significantly (12 per cent) less
when hypothyroid compared to the same patients when
euthyroid (figure 4.3). Mean resting LVEF hypothyroid
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FIGURE 4.3 LVEF at rest and on exercise in the same
patients hypothyroid and euthyroid before
(closed symbols) and after (open symbols)
propranolol. A rise in LVEF with exercise is
maintained when hypothyroid although





was 0.46 +/- 0.02 compared to 0.53 +/- 0.02 euthyroid (P <
0.05). Resting LVEF was the same in both euthyroid
groups and therefore independent of initial thyroid
status. On exercise, LVEF increased in hypothyroid
patients to 0.51 +/- 0.02 (P < 0.05 compared to resting
LVEF). One patient (no. 17) showed no change in LVEF on
exercise and patient 11 showed a modest fall from 0.53 to
0.49. All patients showed an increase in LVEF on
exercise when euthyroid (exercise LVEF 0.58 +/- 0.01 : P
< 0.01 compared to resting LVEF). The magnitude of the
rise in LVEF with exercise was not significantly different
between the two groups.
The fall in LVEF on exercise when hyperthyroid was
maintained after intravenous propranolol (figure 4.2).
The rise in LVEF with exercise when hypothyroid was
slightly reduced after propranolol although differences
did not achieve statistical significance. In both
euthyroid groups, the rise in LVEF on exercise was
attenuated by beta-adrenoceptor blockade (P<0.05). These
changes with exercise are summarised in Figure 4.4.
At rest, there was a significant fall in LVEF after
propranolol (P<0.01) that was similar in hyperthyroid,
hypothyroid and euthyroid groups and therefore appeared to
be independent of thyroid status (Figure 4.5). On
exercise, the fall in LVEF after propranolol was increased
in euthyroid patients but was not significantly changed in
these patients when hyperthyroid or hypothyroid. In
effect, propranolol has attenuated the rise in LVEF with
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FIGURE 4.4 Change in LVEF with exercise in hyperthyroid
and euthyroid patients and in hypothyroid and
euthyroid patients before and after
propranolol. The fall in LVEF with exercise
when hyperthyroid, and the rise in LVEF with
exercise when hypothyroid is not influenced
by beta-adrenoceptor blockade. The increase
in LVEF with exercise when euthyroid is












































exercise only when euthyroid. Beta-adrenoceptor
activation is thus involved in the rise in LVEF during
exercise in the euthyroid state but does not appear to
play an important role in the fall in LVEF in the
hyperthyroid state or the rise when hypothyroid.
Directional changes in the TS:LVET ratio were in
close agreement with and paralleled the LVEF data (Figure
4.6). In the hyperthyroid state, the ratio increased on
exercise (reflecting a reduction in myocardial contractile
activity) both before (from 0.44 +/- 0.02 to 0.47 +/-
0.02: P > 0.05 <0.10) and after ( from 0.44 +/- 0.02 to
0.49 +/- 0.02; P<0.05) propranolol. When hypothyroid, the
ratio reduced from 0.56 +/- 0.02 at rest to 0.52 +/- 0.02
on exercise (P < 0.05) in keeping with the rise in LVEF.
After propranolol, the resting TS:LVET ratio increased to
0.59 +/- 0.02 (P = 0.10) in the hypothyroid group and the
fall on exercise (to 0.56 +/- 0.02) was somewhat reduced.
In the euthyroid state, the TS:LVET ratio fell
significantly on exercise (P < 0.05) irrespective of
initial thyroid status and this fall was maintained after
beta-adrenoceptor blockade (Figure 4.6).
Changes in systolic blood pressure and mean heart
rate are detailed in Table 4.3. No significant
differences in resting or exercise systolic blood pressure
were detectable with differing thyroid status. As
expected, mean heart rate was increased in the
hyperthyroid state at rest (104 +/- 5 beats/minute against
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FIGURE 4.5 The fall in LVEF after propranolol in
hyperthyroid and euthyroid groups at rest
and on exercise. The fall in LVEF with beta-
adrenoceptor blockade is similar at rest and
on exercise in the hyperthyroid and
euthyroid state, but is greater on exercise
when euthyroid.




























Maan HR ^st HP
HHHVwnn
ffeanHRf^st BP
REST 104 125 76 132 67135 79128
+/~5 +/~5 +/~6 +/~6 "*/~4 +/~6 +/-2 +/~6
EXERXE 134160 118 170 97167106167
+/"6 +/~6 +/~6 +/-*7 +/~5 +/~6 +/~4 +/~6
REST(HCEf®lI£Ii) 93120 65128 59131 71123
+/-5 +/~5 +/~4 +/~5 +/~4 +/~6 +/~4 +/-5
EXEROaE(HCH»NICU 118 145 99 153 82 151 90 151
+/~5 +/~6 +/~5 +/~6 +/~6 +/~8 +/~3 +/~5
UBLE 4.3 Heart rate (beat^Amnute) and systolic blood pressure
(nnfig) respcnses to exercise and beta-odrara^bcr
blockade in l^pertiyrcdd and euthyroid patients
before and after corrective therapy.
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76 +/- 6 beats/minute euthyroid; P < 0.005) and reduced
when hypothyroid at rest (67 +/- 4 beats/minute against 79
+/- 2 beats/minute euthyroid; P < 0.05). Relatively
similar changes were observed on exercise. Propranolol
caused a similar reduction in resting heart rate(between
10 and 15 per cent) and exercise heart rate (12 - 16 per
cent) in all groups and attenuated the rise in heart rate
with exercise between 6 and 20 per cent. No significant
differences in the relative change in heart rate with
exercise before or after beta-adrenoceptor blockade were
detectable between the groups.
LVEF showed a positive linear correlation with heart
rate for group data in the hypothyroid and euthyroid
patients and the hyperthyroid patients at rest (r = 0.85;
P < 0.001). On exercise,howeverf the hyperthyroid
patients showed an unexpectedly low LVEF for heart rate
both before and during beta-adrenoceptor blockade (Figure
4.7). Despite similar heart rates, LVEF on exercise at the
same work load was 20 per cent lower (P < 0.002) in the
hyperthyroid group after propranolol (heart rate 118 +/- 5
beats/minute) compared to the same patients euthyroid
prior to beta-adrenoceptor blockade (heart rate 118 +/- 6
beats/minute).
There was no correlation between LVEF or TS:LVET
ratio and plasma thyroid hormone concentrations at any
level of thyroid activity. Resting heart rate was related
to log plasma total thyroxine at all levels of thyroid
dysfunction (r = 0.67; P < 0.005); the relationship was
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FIGURE 4.6 Ts:LVET ratio at rest and on exercise before
and after propranolol in hyperthyroid,
hypothyroid and euthyroid groups. An
increase in the ratio indicates a decrease in
myocardial contractile performance (see
methods) and is noted in hyperthyroid
patients on exercise before and after
propranolol in contrast to a reduction in
euthyroid and hypothyroid patients.
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FIGURE 4.7 The relationship between LVEF and heart rate
in hyperthyroid, hypothyroid and euthyroid
groups before (closed symbols) and during
(open symbols) beta-adrenoceptor blockade.
LVEF is lower than anticipated for heart rate
in the hyperthyroid patients during exercise
(asterisks) .
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closer following propranolol (r = 0.76; P < 0.001)
reflecting removal of the contribution of variable
endogenous sympathetic tone to basal heart rate (Figure
4.8) and therefore greater dependence on thyroid hormone
activity. Correlation between exercise heart rates and
thryoid hormone concentrations did not achieve statistical
significance at a 5 per cent level of confidence.
No abnormalities in regional wall motion were detected
in any patient at rest or on exercise before or after
propranolol.
DISCUSSION
The crucial role of thyroid hormones in adaptive
hypertrophy of the heart has been recognised for many
years (Beznak, 1963). Thyroid hormone feeding in several
animal species leads to myocardial hypertrophy with up to
a 50 per cent increase in heart weight (Sandler and Wilson
1959a; Beznak, 1962; Cohen et al, 1966; Skelton and
Sonnenblick, 1974). Changes are reversible and
independent of sympathetic innervation as they are
unchanged following neuronal blockade with reserpine or 6-
hydroxydopamine (Cohen et al, 1966; Cohen, 1974).
Although no systematic measurements of heart mass before
c
and after treatment have been made in clin i/a 1
hyperthyroidism, electrocardiographic studies have noted
increases in R wave amplitude in up to 30 per cent of
hyperthyroid patients with resolution of changes following
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FIGURE 4.8 The relationship between resting heart rate
after beta-adrenoceptor blockade and plasma
total thyroxine in hyperthyroid (n=9),
hypothyroid (n=8) and euthyroid (n=16)
subjects.
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antithyroid therapy (Sandlerf 1959; Motoki et al, 1966;
Zgliczynski, 1966; Wong et al, 1979). The reduction in
left ventricular voltages in hypothyroidism has been
attributed to minimal pericardial effusion (Kerber and
Sherman, 1975) or increase in electrical resistance of
myxoedematous skin (Hallock, 1933). Although this may be
part of the explanation in selected patients, voltages
return towards normal within 24 hours of triiodothyronine
feeding (Zondek, 1964) favouring a direct effect of
thyroid hormone deficiency on the electrical properties of
cardiac muscle. All of the changes in myocardial
structure described regress following the re-establishment
of a euthyroid state (Skelton and Sonnenblick, 1974). The
presence of myocardial hypertrophy, however, is not
necessarily associated with enhanced contractile
performance (Skelton and Sonnenblick, 1974).
Several investigators have suggested enhanced
myocardial contractile performance in the hyperthyroid
state and impaired peformance when hypothyroid (De Groot
et al, 1961; Aoki et al, 1967; Amidi et al, 1968;
Howitt et al, 1968). Indices of myocardial contractility
derived from measurements of systolic time intervals have
shown a shortened pre-ejection period and isovolumetric
contraction time in hyperthyroidism (Parisi et al, 1974;
Burckhardt et al, 1978) and reciprocal changes in
hypothyroidism (Burckhardt et al, 1978; Paulus et al,
1980) that both return towards normal during therapy.
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None of these studies, however, have assessed myocardial
performance under stress.
The resting observations in the hyperthyroid state in
our study are also in keeping with increased myocardial
contractility. LVEF can, however, be influenced by
changes in preload and afterload as well as contractile
performance. Several haemodynamic studies in
hyperthyroidism at rest have documented a major reduction
«
in peripheral vascular resistance (Abrahamsen et al, 1963;
Ueda et al, 1965; De Groot and Leonard, 1970; Funatsu,
1976) and an increase in circulating blood volume (Gibson
and Harris, 1939),each of which would lead to an increase
in LVEF independent of changes in myocardial
contractility. Merillon et al, (1981), investigated left
ventricular function in hyperthyroidism at rest by cardiac
catheterisation. These workers noted an increase in
cardiac output, LVEF, maximum rate of rise of left
venricular pressure (dP/dt max) and mean velocity of fibre
shortening in hyperthyroidism associated with no change in
mean aortic pressure and a 50 per cent reduction in
peripheral vascular resistance. However, comparision of
hyperthyroid and euthyroid subjects atrially paced to the
same heart rate revealed that the increase in cardiac
output during hyperthyroidism was primarily related to an
increase in left ventricular end-diastolic volume and that
rises in dP/dt max could be secondary to this increase
(Mahler et al, 1975). Their data therefore imply that an
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increase in the inotropic state of the ventricle does not
occur in hyperthyroidism and that many of the findings of
previous investigators could be explained on the basis of
the peripheral effects of thyroid hormone excess,
analogous to changes in other high output states (Duke and
Abelmann, 1969).
The major finding in the present investigation of an
exercise-induced fall in LVEF in hyperthyroidism extends
the studies of Merillon et al to suggest abnormally
depressed myocardial contractile activity. The fall in
LVEF with exercise is not dependent on beta-adrenoceptor
activation because it is similar before and after
propranolol. The absolute LVEF on exercise (at the same
workload) is significantly less in the hyperthyroid
compared to the euthyroid state despite a lower heart rate
in the latter. At the same heart rate (118 beats/min)
exercise LVEF was 20 per cent lower in the hyperthyroid
group after propranolol compared to the same patients
euthyroid before beta-adrenoceptor blockade (figure 4.7).
The changes in LVEF on exercise in the hyperthyroid
patients contrast with the normal responses to exercise
after specific antithyroid therapy, that is a rise in
LVEF on exercise attenuated by beta-adrenoceptor blockade.
This pattern was the same as in the euthyroid patients
after initial hypothyroidism and is well within the normal
range of response in our laboratory.
Although changes in left ventricular volumes have not
been specifically studied in these patients, it is
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unlikely that a change in peripheral vascular resistance
on exercise would explain our results. Peripheral
vascular resistance falls on exercise and should thus
increase LVEF, the opposite of what was observed. Total
end-diastolic counts and the number of cells in the region
of interest of the ventricular volume curve give an index
of diastolic volume: no significant differences with
exercise were detectable between hyperthyroid and
euthyroid groups.
The results in hypothyroidism show, as expected, an
absolute reduction in myocardial contractile performance
at rest and on exercise that appeared to be independent of
beta-adrenoceptor activation and therefore presumably a
direct effect of thyroid hormone deficiency. There were,
however, no significant differences in left ventricular
contractile responses to increased sympathetic tone
(exercise) or to resting sympathetic blockade (
propranolol) in the hypothyroid and euthyroid state.
Attenuation of the rise in LVEF on exercise with
propranolol was less marked when hypothyroid,, possibly
reflecting greater sympathetic activation on exercise in
the hypothyroid state, in keeping with increases in
systemic catecholamines discussed in chapter 1.
Heart rate per se may be a determinant of LVEF in
man (Erhardt et al, 1977; Port et al, 1980) although the
increase in heart rate with atropine has little effect on
LVEF or TssLVET ratio (Muir et al, 1980). A fall in LVEF
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might be caused either by a depression of intrinsic
contractility or a reduction in heart rate. The fall in
LVEF on exercise in the hyperthyroid state occurred
despite an increase in heart rate of approximately 30
beats/minute. Exercise LVEF when hypothyroid was still
slightly less than resting LVEF when euthyroid despite a
substantially higher heart rate in the former group. It
is thus likely that the results reflect a true reduction
in myocardial contractile performance in both states of
thyroid dysfunction.
The development of heart failure in hyperthyroidism
without complicating tachydysrhythmias has now been
established both clinically and experimentally. Piatnek-
Leunissen and Olson (1967) observed that during treatment
of dogs with thyroxine over a period of eight months, 25
per cent of animals developed objective signs of mild
congestive heart failure with a relatively reduced cardiac
output, elevated ventricular end-diastolic pressure and
varying degrees of passive congestion of the lungs and
heart. Clinical (Likoff and Levine, 1943) and autopsy
(Sandler and Wilson, 1959) evidence in man supports, the
existence of heart failure in hyperthyroidism in the
absence of any other complicating heart disease, although
most patients had developed atrial fibrillation prior to
cardiac decompensation. Atrial fibrillation is, however,
very uncommon in neonatal hyperthyroidism, where heart
failure may be a prominent feature (Shapiro et al, 1975).
Ikram (1977) studied seven patients with hyperthyroid
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heart failure and noted significant reductions in cardiac
output, heart rate and right ventricular dP/dt max,
compared to matched patients with uncomplicated
hyperthyroidism. Acute beta-adrenoceptor blockade with
propranolol caused a 30 per cent fall in cardiac output to
subnormal levels in the heart failure group while in the
controls, cardiac output fell by only 13 per cent and
remained above normal. It is assumed that sinus rhythm
persisted during the investigations described in Ikram's
study. It is likely that these differences would be even
greater during exercise (Graettinger et al, 1959).
Histological study of hearts from hyperthyroid patients
and experimental animals does not show a specific pattern
of abnormality, although foci of lymphocytic and
eosinophilic infiltration have been described. Electron
microscopic abnormalities have been mainly confined to the
mitochondria which are frequently increased in number,
hypertrophied, and contain areas of vacuolization and
disorientation of the cristae (Callas and Hayes, 1974).
Changes appear totally reversible on return to the
euthyroid state.
It is probable that isolated hypothyroidism rarely
causes heart failure in the absence of complicating
cardiac disease (Aber and Thompson, 1964), although there
are often clinical difficulties in distinguishing between
"myxoedema heart" and true congestive heart failure. The
ability of LVEF to increase normally on exercise in
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hypothyroidism contrasts with responses in heart failure
(Epstein et al, 1967). Non-invasive assessment of
isolated hypothyroid heart disease is complicated by
clinical (Vanhaelst et al, 1967) and autopsy (Steinberg,
1968) evidence that coronary artery disease occurs more
frequently in hypothyroid patients than in controls
matched for age, sex, blood pressure and associated extra-
thyroidal disorders. This agrees with experimental data
to show that thyroid hormone deficiency consistently
potentiates the development of atherosclerosis in
cholesterol-fed animals (Malmros and Swahn, 1953) and that
thyroid hormone administration can inhibit atherogenesis
(Myasnikov and Zaitzev, 1963). Thyroid hormone
deficiency is associated with raised plasma levels of very
low and low density lipoproteins and impaired free fatty
acid mobilisation principally due to impaired lipoprotein
catabolism (Kritchevsky, 1960; Levy et al, 1974). These
alterations in circulating lipids parallel those
associated with the premature development of coronary
artery disease (Kannel et al, 1976). The incidence of
coronary disease in the hypothyroid patients reported in
this chapter is unknown but it is of interest that the
patient in whom a clinical diagnosis of angina pectoris
was made was the only patient to show a small fall in LVEF
on exercise in the hypothyroid state. A fall in LVEF on
exercise is readily demonstrable in patients with coronary
disease (Marshall et al, 1981). Intriguingly, LVEF
increased normally in this patient when euthyroid.
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Histological study of the myocardium in cases of severe
hypothyroidism shows non-specific changes of myofibrillar
swelling, oedema and interstitial fibrosis (Douglas and
Jacobson, 1957). Although it is possible that
irreversible impairment of cardiac function may develop in
such extreme cases, all of our patients showed a return to
normal function a maximum of eight months after starting
oral thyroxine.
Previous studies into the effects of propranolol on
resting LVEF in normal subjects have yielded conflicting
results, showing either no effect or a depressant effect
on resting ventricular performance (Helfant et al, 1971;
Frishman et al, 1975; Shubrooks et al, 1975; Baron et
al, 1980; Marshall et al, 1981). Differences are
probably related to variability in drug dosage and route
of administration, subject selection and methods of
assessment of contractile performance. On exercise,
propranolol consistently depressed left ventricular
performance probably independent of its effect on heart
rate (Sonnenblick et al, 1965; Erhardt et al, 1977).
Our studies have shown that propranolol did not modify the
pattern of change in contractile performance on exercise,
in either the hyperthyroid or euthyroid state, although
the rise in heart rate on exercise was attenuated. The
exercise-induced tachycardia in hyperthyroidism is
associated with enhanced beta-adrenoceptor mediated
sympathetic activity, while the fall in LVEF on exercise
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is not. It is not clear what components of the complex
central and peripheral circulatory adjustments to exercise
(including sympathetic activation and vagal withdrawal)
are involved in the abnormal responses that have been
documented. It is likely that it is the direct effects of
excess or deficient circulating thyroid hormones that are
the dominent influence on the myocardium.
Propranolol metabolism (Bell et al, 1977) and plasma
protein binding (Kelly and McDevitt, 1978) are not
influenced by thyroid status to any major extent (see
chapter 7). It is thus unlikely that there would be
major differences in plasma propranolol concentrations
after intravenous administration at the three levels of
thyroid activity. A reduction in peak exercise
tachycardia of 13 per cent and 16 per cent in the
hyperthyroid and euthyroid patients and of 16 per cent and
15 per cent in the hypothyroid and euthyroid patients
respectively suggests similar functional beta-adrenoceptor
antagonism in both groups. The dose of propranolol used
(0.15 mg/kg) has been shown to cause a 20 to 30 fold
increase in the isoprenaline dose required to increase the
heart rate by 25 beats/min and to give plasma propranolol
concentrations in the range 50-100 ng/ml (Coltart and
Shand, 1970), suggesting satisfactory beta-adrenoceptor
blockade over the study periods. Chronic propranolol
administration causes a fall in levels of circulating T3
and a rise in levels of the metabolically inactive
stereoisomer 'reverse' T3 (see chapter 2). It is
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unlikely, however, that acute drug administration would
alter plasma thyroid hormone levels sufficient to
influence the cardiovascular responses at rest or on
exercise through this mechanism.
The results highlight the major differences in
cardiovascular effects of anti-thyroid or thyroxine
replacement therapy on one hand and beta-adrenoceptor
blockade on the other. None of the thyroid hormone
related abnormalities in myocardial contractility were
modified by beta-adrenoceptor blockade whereas all were
restored to normal following attainment of the euthyroid
state.
The clinical significance of these observations is
unclear but may provide an explanation for the common
symptoms of impaired exercise tolerance in
hyperthyroidism. A fall in ventricular contractile
performance on exercise is readily demonstrable in
patients with coronary artery disease although the
pathophysiological basis for this finding is more easily
understood (Battler et al, 1979; Marshall et al, 1981).
An abnormal LVEF on exercise has been suggested as an
early index of left ventricular dysfunction in patients
with asymptomatic aortic regurgitation (Borer et al, 1978)
and with chronic iron overload (Leon et al, 1979). It
may be that left ventricular dysfunction induced by
exercise represents an intermediate state between normal
left ventricular function and left ventricular dysfunction
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at rest. It is at present unknown whether hyperthyroid
patients, if untreated, would develop resting
abnormalities and a true thyroid cardiomyopathy.
Our data provide evidence for the existence of a form
of reversible cardiomyopathy in all patients with
hyperthyroidism, manifest as an abnormal fall in LVEF on
exercise, independent of beta-adrenoceptor activation.
Left ventricular function is also reversibly depressed by
thyroid hormone deficiency but relative responses to
exercise before and during beta-adrenoceptor blockade are
unimpaired. There is no evidence of altered adrenergic
sensitivity in the control of myocardial contractile
function during thyroid dysfunction. Thus, changes in
adrenoceptor density, if they occur in man, are not
associated with a change in the contractile response of
the heart to altered sympathetic tone. Depression of
myocardial contractile activity is detectable in different
forms in both hyper- and hypothyroidism. Clinical
evidence of contractile dysfunction in thyroid disease may
simply represent one end of the spectrum of abnormality
common to all patients with this disorder.
Addendum:
Since this thesis was completed, LVEF has been assessed in eight
of the nine patients, initially hyperthyroid, who were restudied during
exercise to the same heart rate as that achieved when hyperthyroid ( 134
+/- 6 beats / min ]. Exercise LVEF at this heart rate when euthyroid
was 0.66 +/- 0.03, substantially greater than when hyperthyroid ( 0.55
+/- 0.02 ; P< 0.01 ]. This data also supports the concept of depressed




Delayed normalisation of ventricular function during
antithyroid therapy: echophonocardiographic analysis of
responses to isometric exercise and autonomic blockade.
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As discussed briefly in the previous
chapter, assessment of intrinsic contractile function of
the heart in hyperthyroidism is complicated by changes
in preload from increased circulating blood volume and
changes in afterload from reduced peripheral vascular
resistance. Thus, Merillon et al (1981) noted a 34 per
cent increase in left ventricular end-diastolic
volume and a 46 per cent fall in peripheral vascular
resistance in hyperthyroid subjects compared to euthyroid
subjects atrially paced to the same heart rate.
Interpretation of indices of ventricular function at
rest is therefore unreliable. Isovolumetric phase
indices of contractility such as the maximum rate of
rise of ventricular pressure (dp/dt max), dp/dt at a given
pressure, or pre-ejection period indices from systolic
time intervals appear to be particularly affected by
alteration in preload (such as acute volume overload),
whereas ejection phase indices such as ejection fraction
or mean velocity of circumferential fibre shortening
(Vcf) are more influenced by changes in afterload
(such as phenylephrine infusion) (Mahler et al, 1976).
It has been claimed that ejection phase indices such as
Vcf are independent of preload (Ross and Peterson, 1973;
Quinones et al, 1975) and are preferable to
isovolumetric indices in the detection of patients with
diffuse myocardial disease (Karliner et al, 1971; Peterson
et al, 1974).
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Isometric exercise, such as sustained
handgrip, provides a convenient means of inducing a
significant stress on the myocardium. Myocardial
oxygen consumption is increased through a combination
of increased afterload, inotropic activity and heart
rate, the latter mediated as much by vagal withdrawal
as by sympathetic activation (Freyschuss, 1970). In
these respects, isometric exercise differ s considerably
from dynamic exercise and may be a more effective and
reproducible form of stress on the heart (Lindquist et
al, 1973). It is readily applicable to echocardiograhic
techniques that provide an accurate, simple and non¬
invasive assessment of myocardial dimensions and
contractile function (Cooper et al, 1972; Belenkie et
al, 1973; Fortuin et al, 1977).
The purpose of this investigation was to
examine simultaneously isovolumetric and ejection phase
indices of myocardial contractile function before
and during isometric exercise in hyperthyroid patients
using the combined technique of echophonocardiography.
This totally non-invasive method of assessment can be
repeated at intervals during antithyroid therapy to
establish the pattern of change in ventricular
function with respect to thyroid activity. In addition,
the effect of autonomic blockade was examined to determine
the influence of vagosympathetic activity on the
responses to isometric exercise. The study was
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designed both to confirm or refute the
abnormalities on dynamic exercise shown in chapter 4, and
to determine by prospective longitudinal analysis whether
there was a direct temporal relationship between thyroid
hormone concentrations and myocardial function, as has
been claimed by other investigators (Paulus et al, 1980;
Cohen et al, 1981).
METHODS
Fifteen hyperthyroid patients, all women, with a
mean age of 45 years (range 23-65 years) were studied
in the untreated hyperthyroid state and at intervals
during antithyroid therapy. Eleven patients had Graves'
disease and four had a toxic multinodular goitre.
Hyperthyroidism was diagnosed clinically and on the basis
of raised levels of plasma total thyroxine (T4) and
triiodothyronine (T3) associated with an absent response
of plasma thyrotrophin (TSH) 20 minutes after the
intravenous injection of 200ug thyrotrophin-releasing
hormone and increased four hour uptake of iodine 132 by
the thyroid gland. No patient had evidence of
concurrent cardiovascular disease based on clinical
examination, ECG and chest X-ray although two patients
(nos. 2 and 6) had clinical evidence of mitral valve
P
prolapse, confirmed by echocardiography. The
echocardiographic appearances were not modified by
antithyroid therapy. All patients were restudied when a
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biochemical euthyroid state had been achieved for at
least three months. Eleven patients received a
therapeutic dose of iodine 131, two patients received
carbimazole and one underwent a subtotal thyroidectomy. A
euthyroid state developed spontaneously in patient no. 3.
In addition, nine of these patients were studied on a
total of 19 occasions at 3-6 week intervals during
antithyroid therapy prior to the establishment of a stable
euthyroid state.
At each outpatient attendance, blood was withdrawn
for estimation of plasma total T4, T3 and plasma TSH
immediately prior to the echophonocardiographic study.
Plasma thyroid hormones and TSH were measured by specific
radioimmunoassay (Irvine et al, 1973; Seth et al, 1976) as
described in chapter 2.
All patients gave informed consent to participate and
were familiarised with the recording equipment prior to
the first study. After a ten minute rest period and
insertion of a peripheral venous infusion cannula,
systolic time interval measurements were recorded in the
supine position according to established techniques (Lewis
et al, 1977) using a Kontron Irex Mark III combined
echocardiography / phonocardiography instrument with
appropriate frequency filters. All recordings were made
at a paper speed of 100mm per second (Spodick et al, 1969)
and averaged over at least 10 cardiac cycles to minimise
respiratory variation. From simultaneous recordings of
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the electrocardiogram (lead II), phonocardiogram and
carotid pulse tracings, the following parameters were
measured:
1) Left ventricular ejection time (LVET) - from the
beginning of the initial upstroke to the trough of
the incisural notch of the carotid pulse tracing.
2) Total electromechanical systole (QS2) " from the
beginning of the Q wave of the electrocardiogram to
the first high frequency component of the aortic
component of the second heart sound.
3) Electromechanical delay (QS^) - from the beginning of
the Q wave of the electrocardiogram to the first high
frequency component of the first heart sound.
From these measurements, the preejection period
(PEP) [QS2-LVET] and the isovolumetric contraction time
(ICT) [PEP-QS1] were determined (figure 5.1). Heart
rate-corrected indices for LVET, QS2 and PEP were
derived from the standard regression equations
of Weissler et al (1968), based on measurements from
resting normal subjects and also on the studies of
Lindquist et al (1973) with normal subjects during
isometric exercise. Only those recordings clearly
showing the onset of the Q-wave, the first high
frequency vibrations of the heart sounds and a sharp
upstroke and incisura of the carotid tracings were used
for measurement of the above parameters. All measurements
were made to the nearest five milliseconds (msecs).
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FIGURE 5.1 Simultaneous determination of systolic time
intervals from carotid pulse,
phonocardiogram and electrocardiogram
tracings (upper panel) and determination of
left ventricular dimensions from M-mode
echocardiogram (lower panel).
LVET-left ventricular ejection time: QSj-
electromechanical delay: PEP-preejection
period: ICT-isovolumetric contraction time:
LVEDD/LVESD-left ventricular end-diastolic /
end-systolic dimensions: RV-right ventricle:
IVS- interventricular septum: LV-left




Echocardiography was performed from the third
or fourth intercostal space either supine or in the
30° left lateral decubitus position immediately
following the systolic time interval measurements.
An initial two-dimensional examination using a phased
array scanner was used for orientation of the M-mode
examination of the left ventricular chamber. Thereafter,
a 2.5 megahertz single element transducer was used and
left ventricular wall motion recorded with the
ultrasound beam directed at the chamber between the
mitral valve echoes and the papilliary muscle echoes
(figure 5.1? Sahn et al, 1978). Left ventricular
end-diastolic dimension (LVEDD) was taken from the
trailing edge of the left side of the interventricular
septum to the leading edge of the posterior endocardial
echo at the R wave of the electrocardiogram and left
ventricular end-systolic dimension (LVESD) from the same
sites at the time of peak upward motion of the posterior
left ventricular endocardium (Feigenbaum, 1981). From
these measurements, the mean velocity of circumferential
shortening of the left ventricle (Vcf) was derived
according to the following equation:-
LVEDD - LVESD
Vcf = (circumferences /sec.)
LVEDD X LVET
The patient and transducer position for optimal
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recording were noted for each subject at the time of
initial study, and these were duplicated for subsequent
echocardiograms. All values were averaged over a
minimum of five consecutive cardiac cycles.
Systolic blood pressure was determined at rest using a
mercury sphygmomanometer, the cuff being placed on the
arm not used for the isometric test.
Following the basal measurements, isometric exercise
was performed with a handgrip dynamometer (Department of
Medical Physics, RIE) held at arms length with the arm
supported. After first determining maximum voluntary
contraction (MVC) each patient squeezed the dynamometer at
30 per cent of the MVC for a period of three minutes.
Systolic blood pressure measurements were repeated after
two minutes and the echophonocardiographic analysis
between the second and third minutes of handgrip. Care
was taken to ensure that the orientation of the
transducer was similar during the rest and exercise
echocardiogram.
In most patients, after a further 15 minute rest
period, propranolol 0.15 mg/kg was given intravenously
over five minutes followed by intravenous atropine 0.02
mg/kg over a similar period. Fifteen minutes later, the
above protocol was repeated both at rest and during
isometric exercise.
Identical studies were repeated at intervals during
antithyroid therapy and when a biochemical euthyroid state
had been achieved for at least three months. Acute
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autonomic blockade was omitted in patient no. 1 because of
mild asthma and in patient no.5 for studies 2, 3 and 4
because of dizziness during the initial study. In
addition, patients receiving concurrent oral beta-
adrenoceptor blocking agents as part of the routine early
management of hyperthyroidism (patient no. 4, study 2;
patient no. 11, studies 2, 3 and 4) were not subject to
additional autonomic blockade. The data obtained at these
times were included with the other studies during
autonomic blockade.
Echophonocardiographic measurements were therefore
repeated at intervals over several months. Although
reproducibility studies were not performed on these
patients, others (Lewis et al, 1974; Clark et al, 1980;
Cohen et al, 1981) have demonstrated a small mean standard
deviation for systolic time intervals (e.g. +/- 5 msecs
for LVET; +/- 4.3 msecs for PEP) and Vcf (+/- 0.05
circumferences per sec) when repeated over days and weeks
in the same healthy subjects. A preliminary study
undertaken on four normal subjects on four separate
occasions using the above protocol showed similar day to
day variability in these parameters.
All measurements of ventricular function during
antithyroid therapy were made without knowledge of thyroid
hormone concentrations or current antithyroid treatment.
Statistical analysis used Students t-test for pair
differences. Correlations between thyroid hormones and
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indices of ventricular function used a linear regression
coefficient with least squares method of analysis and
computed t-statistic after semilog transformation.
Experimental data are quoted as mean +/- SEX.
RESULTS
Untreated hyperthyroidism
Details of systolic time intervals, systolic blood
pressure, heart rate, ventricular dimensions and the
derived indices of ventricular function at rest and during
isometric exercise are shown in tables 5.1 and 5.2.
Systolic time interval indices (corrected for heart rate)
for QS2r LVET and PEP have been calculated according to
theregression equations of Weissler et al (1968) at rest
and from those of Lindquist et al (1973) during isometric
exercise.
At rest, absolute mean LVET was relatively short at
253 +/- 6 msecs but LVETI was not significantly different
from that predicted (418 +/- 11 msecs) either before (413
+/- 5 msecs) or during (408 +/-7 msecs) autonomic
blockade. LVET did not change with isometric exercise,
and LVETI, using the Lindquist equation (based on normal
subjects during isometric exercise) was not significantly
different from normal either before (exercise LVETI 377
+/- 6 msecs) or after (exercise LVETI 374 +/- 3 msecs)
autonomic blockade (predicted LVETI 379 +/~ 14 msecs).






Patients 15 15 14 14
Syst BP(irmHg) 126 151 115 126
+/-5 +/-5 +/~4 +/~3
HR(beats/min) 99 108 85 90
+/—4 +/—5 +/—4 +/-4
LVET (msecs) 253 252 266 266
+/-€ +/~5 +/~6 +/-€
LVETI (Weissler) 413 - 408
+/-5 +/"7
LVETI(Lindquist) - 377 - 374
+/—6 +/~3
QS2 (msecs) 324 331 348 362
+/-8 +/-8 +/"8 +/-8
QS2I (Weissler) 522 - 518
+/-14 +/-12
QS2I(Lindquist) - 525 - 520
+/-6 +/-7
PEP (msecs) 71 79 81 95
+/-4 +/-5 +/-5 +/-5
PEPI (Weissler) 111 - 117
+/-4 +/-5
PEPI (Lindquist) - 144 - 149
+/-4 +/-5
ICT (msecs) 30 37 39 46
+/-3 +/-3 +/-3 +/-3
PEP:LVET 0.28 0.31 0.30 0.36
+/-.02 +/-.01 +/-.02 +/-.02
TABLE 5.1 Systolic blood pressure, heart rate and systolic time interval
measurements (mean+/~SEM) in untreated hyperthyroid patients
at rest and during handgrip isometric exercise before and
after autonomic blockade (see text for abbreviations).
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unlike the ejection time values, QS2 was significantly
less than predicted (resting QS2I 522 +/- 14 msecs;
predicted QS2I 549 +/- 3 msecs: P<0.01). In contrast,
QS2I was significantly greater than predicted during
isometric exercise (exercise QS2I 525 +/- 6 msecs;
predicted QS2I 514 +/- 6: P<0.05). Mean QS2 at rest
increased by 24 msecs during autonomic blockade in keeping
with a fall in heart rate from 99 to 85 beats per minute.
QS2I at rest was not influenced by autonomic blockade. On
exercise after autonomic blockade, however, the QS2I was
also greater than predicted (520 +/- 7 msecs; P<0.05).
As a consequence of the changes in electromechanical
systole, both PEP and PEPI were shorter than predicted in
h
the resting hypert,yroid state before (PEPI 111 +/- 4
msecs; predicted PEPI 133 +/- 10 msecs) and during (PEPI
117 +/- 5 msecs) autonomic blockade. On exercise, PEP
increased from 71 +/- 4 to 79 +/- 5 msecs with a
substantial increase in PEPI from 111 +/- 4 to 144 +/- 4
msecs (PC0.005). The exercise PEPI was 9 msecs longer
than predicted from the regression equation (predicted
PEPI 135 +/- 13 msecs). This increase resulted mainly
from an increase in isovolumetric contraction time (table
5.1). The pattern of prolongation in PEP and PEPI on
exercise was similar during autonomic blockade. PEPI
increased from 117 +/- 5 to 149 +/- 5 msecs (P<0.005).
The PEP:LVET ratio increased on exercise before and after
autonomic blockade (table 5.1).
Left ventricular end-diastolic dimensions were not
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UNTREATED AUTONOMIC BLOCKADE
REST EXERCISE REST EXERCISE
LVID (cms)
DIASTOLE 4.2 4.3 4.2 4.2
+/-0.2 +/-0.1 +/-0.1 +/-0.1
SYSTOLE 2.7 3.2 3.2 3.3
+/-0.1 +/-0.2 +/-0.1 +/-0.1
Vcf (circ/sec) 1.40 1.01 0.90 0.78
+/-0.10 +/-0.09 +/-0.05 +/-0.05
TABLE 5.2 Left ventricular systolic and diastolic dimensions
and derived velocity of circumferential fibre
shortening (Vcf) in untreated hyperthyroid patients
at rest and during isometric exercise before and
after autonomic blockade.
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influenced by exercise or autonomic blockade (table 5.2).
Exercise and autonomic blockade alone increased left
ventricular end-systolic dimensions (2.7 +/- 0.1 cms rest;
3.2 +/- 0.2 cms exercise; 3.2 +/- 0.1 cms autonomic
blockade [PC0.01]) with a further minor increase in
combination (3.3 +/- 0.1 cms). As a result, mean Vcf
decreased on exercise by 30 per cent before and by 13 per
cent after autonomic blockade. As might be anticipated,
resting Vcf also decreased (by 33 per cent) with autonomic
blockade (table 5.2).
The changes in these parameters with exercise are
summarised in figure 5.2. Systolic time intervals have
been presented as indices, with predicted values ( +/- 1
SD) shown for comparison. PEPI has thus changed
substantially with exercise from 21 +/- 3 msecs less than
predicted to 9 msecs greater than predicted (P<0.01), with
similar^>rolongation/on|lexercise|with autonomic blockade.
Established euthyroid state
The same parameters of ventricular function in the
same patients after a euthyroid state had been achieved
for at least three months are presented in tables 5.3 and
5.4 and summarised in figure 5.3. Compared to the
hyperthyroid state, resting LVETI was unchanged but QS2I
was significantly prolonged both before (aQS2I 20 +/- 11
msecs; P<0.05) and after (aQS2I 36 +/- 12 msecs, PC0.02)
autonomic blockade. A striking prolongation of the PEPI
was also observed in the euthyroid patients at rest (A
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FIGURE 5.2 Mean (+/- SEM) systolic time interval indices
(LVETI, Q S oIr PEPI) and velocity of
circumferential shortening of the left
ventricle (Vcf) in 15 hyperthyroid patients
at rest and with isometric exercise before
(Cont.) and after (Aut. Bl.) autonomic
blockade. Predicted values (+/- SD) for
















REST EXERCISE REST EXERCISE
Patients 15 15 13 13
Syst BP(nmHg) 119 144 114 130
+/-6 +/-10 +/-6 +/-8
HR(beats/rain) 82 93 71 74
+/-6 +/-7 +/-4 +/~7
LVET(msecs) 279 280 295 298
+/-7 +/-8 +/-5 +/-7
LVETI(Weissler) 410 - 409
+/-6 +/~6
LVETI(Lindquist) - 387 - 384
+/-8 +/-8
QS^tnisecs) 378 363 410 393
+/-9 +/-10 +/-10 +/"6
QSoItWeissler) 542 - 554 -
+/-13 +/-11
QSol (Lindquist) - 526 - 522
+/-H +/-7
PEP(msecs) 98 80 118 95
+/-8 +/-5 +/-9 +/-5
PEPI(Weissler) 130 - 146
+/"6 +/~9
PEPI (Lindquist) - 135 - 139
+/-4 +/-4
ICT(msecs) 56 41 72 69
+/-5 +/-4 +/-7 +/-7
PEPrLVET 0.34 0.29 0.39 0.32
+/-0.02 +/-0.02 +/-0.03 +/-0.02
TABLE 5.3 Systolic blood pressure,heart rate and systolic time interval
measurements (mean+/~SEM) in patients when euthyroid at rest
and during isometric exercise before and after autonomic







DIASTOLE 4.0 4.1 4.1 4.2
+/-0.2 +/-0.2 +/-0.2 +/-0.2
SYSTOLE 3.0 2.9 3.2 3.2
+/-0.1 +/-0.2 +/-0.2 +/-0.2
Vcf (circ/sec) 0.90 1.02 0.73 0.79
+/-0.10 +/-0.10 +/-0.14 +/-0.16
TABLE 5.4 Left ventricular systolic and diastolic dimensions
and derived velocity of circumferential fibre
shortening (Vcf) in euthyroid patients at rest
and during isometric exercise before and after
autonomic blockade.
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PEPI [euthyroid - .hyperthyroid] 19 +/- 6 msecs before and
29 +/- 9 msecs after autonomic blockade). On exercise
LVETI in the euthyroid patients was slightly longer than
when hyperthyroid but results did not achieve statistical
significance at a 5 per cent level of confidence. In
direct contrast to the hyperthyroid data, however,
exercise PEPI was shorter in the euthyroid state both
before (exercise PEPI euthyroid 135 +/- 4 msecs; exercise
PEPI hyperthyroid 144 +/- 4 msecs; P<0.05) and after
(exercise PEPI euthyroid 139 +/- 4 msecs; exercise PEPI
hyperthyroid 149 +/- 5 msecs; P<0.05) autonomic blockade.
This is reflected in an 11 per cent prolongation of PEP on
exercise when hyperthyroid, compared with an 18 per cent
reduction in PEP when euthyroid, despite similar increases
in heart rate at both levels of thyroid function. It is
likely that the majority of these differences are
accounted for by changes in isovolumetric contraction time
(table 5.3).
Mean resting Vcf fell when euthyroid by 36 per cent
(table 5.4) but in contrast to the exercise-induced fall
in the hyperthyroid state, Vcf did not change with
exercise either before or after autonomic blockade.
Propranolol and atropine increased left ventricularend-
systolic diameter at both levels of thyroid function but
end-diastolic diameter was unchanged. There was a trend
for an increased left ventricular end-diastolic diameter
in the hyperthyroid state but this increase did not quite
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FIGURE 5.3 Systolic time interval indices and velocity
of circumferential shortening of the left
ventricle in the same patients as shown in
figure 5.2 after a biochemical euthyroid
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achieve statistical significance (0.1>P>0.05). Left
ventricular end-systolic diameter was less than control
when hyperthyroid at rest but slightly greater than
control on exercise. Thus, mean Vcf on exercise was
similar in both hyperthyroid and euthyroid groups (table
5.2 and table 5.4).
All of the systolic time interval index measurements
in the euthyroid patients at rest and on exercise prior to
autonomic blockade were within one standard deviation of
the expected mean, based on analysis of normal subjects.
Ventricular function - thyroid hormone relationships
A fairly close inverse correlation was observed
between resting PEPI and levels of thyroid hormones in
hyperthyroid and euthyroid patients, both before and
during autonomic blockade (figure 5.4). A similar but
direct relationship existed for Vcf (figure 5.5).
Although triiodothyronine is the physiologically more
active hormone, plasma thyroxine has been used for
correlations because of the relatively large number of
patients (6 out of 15) on permanent thyroxine replacement
therapy when euthyroid.
On exercise, and in contrast to the resting data,
neither isovolumetric nor ejection phase indices of
ventricular function correlated significantly with plasma
thyroid hormones before or after autonomic blockade.
However, the change in PEPI and Vcf with exercise
correlated with thyroid hormone level before and during
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FIGURE 5.4 Plasma thyroxine and resting preejection
period index in hyperthyroid patients and
the same patients euthyroid before (upper
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FIGURE 5.5 Plasma thyroxine and resting mean velocity of
circumferential shortening of the left
ventricle in hyperthyroid patients and the
same patients euthyroid before (upper panel)




autonomic blockade, the relationship being closest after
propranolol and atropine (figure 5.6).
Ventricular function during antithyroid therapy
In four of the nine patiei^b studied on 4-6 occasions
p
during antithyroid thera,y, temporal dissociation was
evident between the fall in thyroid hormone concentrations
-e.
towards normal and improvement in myocardial contractile
function on exercise. An example of this dissociation
(patient no.11) is shown in figure 5.7. Thyroid hormone
levels returned to normal 60 days after antithyroid
therapy (1131) but ventricular function on exercise
remained abnormal for several weeks thereafter and did not
fall with the expected normal range until 140 days after
initial radioiodine treatment.
A similar dissociation was evident in patient no. 9,
who developed hypothyroidism after radioiodine (figure
5.8). Responses to exercise were similar to the response
when initially hyperthyroid during the first study when
biochemically hypothyroid but similar to responses when
euthyroid during the second study despite similar
depression of thyroid activity.
Clear dissociation between thyroid hormone
concentrations and ventricular function during antithyroid
therapy could not be identified in the other patients,
probably because echophonocardiographic analysis was not
undertaken sufficiently frequently for adequate assessment
of this relationship.
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FIGURE 5.6 Plasma thyroxine and exercise-induced changes
in isovolumetric (PEPI) and ejection (Vcf)
phase indices of ventricular function during
autonomic blockade in hyperthyroid and
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FIGURE 5.7 Comparison between thyroid hormone
concentrations and responses of
isovolumetric and ejection phase indices
of ventricular contraction to exercise in
one hyperthyroid patient (no.11) during
antithyroid therapy. A positive change in
preejection period index (PEPI) with
exercise and a negative change in mean
velocity of circumferential shortening
(Vcf) on exercise both represent
reductions in myocardial contractile
function.Plasmathyroid hormones return
to normal within 60 days ofstarting
antithyroid therapy but ventricular
function on exercise is not within the







































Several previous studies have documented similar
changes in resting systolic time interval and
echocardiograhic measurements of ventricular function to
those reported here. Nearly all investigators have shown
reductions in the PEP (Parisi et al, 1974; Hillis et al,
1975; Burckhardt et al, 1978; Chakravarty et al, 1978;
Paulus et al, 1980; Cohen et al, 1981) in hyperthyroidism
from a reduction in electromechanical systole and usually
little change in left ventricular ejection time. In all
studies, the PEPI has been 20-40 msecs less than that
predicted for heart rate, a reduction that has generally
been interpreted to be secondary to an increase in
intrinsic myocardial contractile activity. Similarly,
echocardiographic indices of myocardial contractile
function at rest have uniformly shown augmented velocity
of shortening of the left ventricle that returns to normal
after a stable euthyroid state has been achieved (Lewis et
al, 1979; Cohen et al, 1981). The interpretation of these
data solely in terms of increased intrinsic contractile
activity of the heart is simplistic and cannot be upheld
in the light of the peripheral haemodynamic effects of
thyroid hormones. Thus, the substantial reduction in
peripheral vascular resistance at rest (Graettinger et al,
1959; Merillon et al, 1981) and increases in circulating
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FIGURE5.8 Comparison between thyroid hormone
concentrations and responses to exercise of
isovolumetric and ejection phase indices of
ventricular function in patient no.9.
Hypothyroidism developed after the second
dose of radioiodine and persisted for
studies 3 and 4; responses to exercise at
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blood volume (Gibson and Harris, 1939) would tend to
shorten isovolumetric phase indices and increase ejection
phase indices of myocardial contractility independent of
any true change in the contractile state of the heart.
In this regard, it is of interest that the extent of the
shortening in PEPI in hyperthyroidism is greater than that
shown with specific inotropic agents (Weissler et al,
1965; Weissler et al, 1972). Graettinger in 1959 reported
a normal cardiac output in hyperthyroid patients who had
congestive heart failure in contrast to an increased
output in patients without evidence of heart failure.
Although the maximum rate of rise of left ventricular
pressure (dp/dt) and left ventricular ejection fraction
(LVEP) were increased in hyperthyroidism at rest in the
study of Merillon et al (1981), comparison with euthyroid
controls atrially paced to the same heart rate showed that
LVEF, dp/dt as a proportion of total pressure, mean Vcf
and the ratio of left ventricular end-systolic pressure
and volume were similar in both groups. The latter
parameter of ventricular function in particular provides a
sensitive index of performance of the left ventricular
pump (Suga and Sagawa, 1974). One study (Ueda et al,
1965) has noted a dilated left ventricle (increased end-
diastolic volume) with a normal or reduced LVEF in
hyperthyroidism. Interpretation of resting parameters of
ventricular function is thus unreliable in this condition.
In contrast, during isometric exercise, this study
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has shown substantial prolongation of the PEP and PEPI and
fall in Vcf in hyperthyroid patients. The isovolumetric
phase index increased with exercise to a level
significantly greater than that predicted for heart rate
from normal subjects according to the regression equation
of Lindquist et al (1973) and the reduction in ejection
phase index of contractility on exercise contrasted with
no change in the velocity of ventricular shortening when
euthyroid. Both of these independent observations suggest
impairment of intrinsic myocardial contractile performance
under stress in hyperthyroidism, and support the data
presented in chapter 4. External measurement of the
preejection period correlates closely with direct internal
measurements of this interval under a variety of different
loading conditions of the heart (Martin et al, 1971). The
prolongation in PEP and PEPI on exercise contrasts with
either no change or reductions in these measurements in
the same patients when euthyroid and in other studies in
normal subjects and those with coronary artery disease
(Siegel et al, 1972; Quarry and Spodick, 1974). Invasive
assessment of responses to isometric handgrip exercise
have shown no changes in stroke volume or stroke index in
normal subjects, contrasting with a significant fall in
these parameters in patients with heart disease (Helfant
et al, 1971). Although isolated increases in afterload
(e.g. with angiotensin infusion ) tend to reduce Vcf in
normal subjects (Quinones et al, 1975), this is offset
during isometric exercise by increases in cardiac
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sympathetic tone and contractility, and hence little net
change in Vcf is observed with this manoevre, in contrast
to responses in hyperthyroidism.
Several studies have demonstrated a correlation
between levels of peripheral thyroid hormones and indices
of ventricular function at rest before and after
antithyroid therapy (Parisi et al, 1974; Crowle y et al,
1977 ; Paulus et al, 1980; Cohen et al, 1981) a
relationship confirmed here. It is likely, however, in
view of responses to exercise, that this reflects dose
dependent effects of thyroid hormones on peripheral
vascular haemodynamics, rather than on the heart itself.
It is probable that many of the clinical features of
hyperthyroidism reflect this action of thyroid hormone
excess (Merillon et al, 1981). The relationship would be
closest for free triiodothyronine but is maintained for
total thyroxine both before and after autonomic blockade
(figure 5.4 and 5.5).
No such relationship for PEPI and Vcf is evident on
exercise although the change in these parameters on
exercise is related to levels of thyroid hormones (figure
5.6) such that the greater the levels of hormones, the
greater the impairment of exercise response. These
results suggest that at least a component of this abnormal
response on exercise is dependent on the degree of
hyperthyroidism, as reflected by peripheral hormone
concentration.
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Acute autonomic blockade and antithyroid therapy with
establishment of a euthyroid state have fundamentally
different actions on the heart in hyperthyroidism. While
both interventions were associated with an increase in
resting PEPI the magnitude of change in PEPI was over
three times greater after antithyroid therapy than
autonomic blockade. Changes in resting Vcf were however,
similar with autonomic blockade and antithyroid therapy,
again highlighting the importance of peripheral factors in
determining isovolumetric parameters of ventricular
function. The increase in resting left ventricular end-
systolic diameter was the major factor contributing to the
fall in Vcf with autonomic blockade, while the fall with
antithyroid therapy depended on a combination of a
decrease in left ventricular end-diastolic diameter and
increase in end-systolic diameter. These changes are in
agreement with the invasive studies of Merillon et al
(1981). On exercise, the contrast between autonomic
blockade and antithyroid therapy is more striking.
Directional changes in parameters of ventricular function
were not influenced by autonomic blockade in
hyperthyroidism, with the increase in PEPI and reduction
in Vcf on exercise similar to that prior to autonomic
blockade. Antithyroid therapy, however, led to
normalisation of responses to exercise, provided that a
euthyroid state had been achieved for some months.
While the magnitude of the reduction in myocardial
contractile activity on exercise was related to peripheral
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hormone concentrations in the untreated hyperthyroid state
(figure 5.6), the relationship broke down during
antithyroid therapy (figures 5.7 and 5.8) suggesting that
factors other than hormone concentration per se determine
contractile activity at this time. This delayed
normalisation of left ventricular function supports the
concept of structural changes in the hyperthyroid heart
(determined perhaps as much by the duration of
hyperthyroidism as by the levels of thyroid hormones) that
resolve at a rate significantly slower than the
hyperthyroidism itself. Young et al (1976) noted delays
of up to two months in normalisation of the arterial sound
times in hyperthyroid subjects studied repeatedly during
antithyroid therapy, in keeping with the observation of
Chakravarty et al (1978) that plasma thyroxine levels
returned to normal some weeks before PEPI when
hyp othyroid patients were followed during thyroxine
replacement therapy. No previous studies have assessed
responses to exercise in thyroid disease.
The results presented in chapters 4 and 5 permit the
development of a new hypothesis of myocardial function in
hyperthyroidism that may be stated as follows
"Left ventricular function is reversibly depressed in
hyperthyroidism evidenced by abnormalities in
isovolumetric and ejection phase indices of contractile
activity during static and dynamic exercise that return
to normal only after a stable euthyroid state has been
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achieved for at least three months. The apparent changes
in indices of contractile activity at rest are spurious
and are primarily related to the profound peripheral
effects of thyroid hormones. Autonomic blockade causes
similar reductions in myocardial contractile function in
the hyperthyroid and euthyroid state without influencing
directional responses to exercise. No evidence of a
specific thyroid autonomic interaction is observed."
This hypothesis has the advantage of explaining the well
established clinical observation of heart failure in
uncomplicated hyperthyroidism (Graettinger et al, 1959;
Ueda et al, 1965; Ikram, 1977) that may be considered one
end of a range of depression of myocardial contractility,
rather than an idiosyncratic reaction to thyroid hormone
excess. The studies are, however, at variance with
results in experimental hyperthyroidism suggesting that
these may have limited application to man either because
of the uniformly short duration of thyroid hormone feeding
or because of some unidentified cardiodepressant factor
operative clinically but not when the disease is mimicked
by thyroxine or triiodothyronine administration. Ideally,
further resting studies in hyperthyroid and euthyroid
groups during similar loading conditions of the heart
would be necessary to confirm abnormal ventricular
function at rest but this would require combined volume
loading and substantial afterload reduction in the latter
group, both of which would be difficult to achieve. The
studies underline further the importance of early
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diagnosis and treatment of hyperthyroidism as one may
speculate that ,left untreated, the abnormalities in




Cardiovascular Responses in Hyperthyroidism before and
during Beta-adrenoceptor Blockade: Evidence against
Adrenergic Hypersensitivity.
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A relationship between excessive sympathoadrenal
activity and hyperthyroidism has been suggested for many
years because of the similar clinical effects of
catecholamines and thyroid hormones discussed in chapter
1. Despite extensive study, controversy remains about
the effects of thyroid hormones on myocardial sensitivity
to catecholamines (Van der Schoot and Horan, 1965;
Levey, 1971).
It has been tempting to infer adrenergic
hypersensitivity in experimental hyperthyroidism from
radioligand binding studies showing increased beta-
adrenoceptor density in hyperthyroid hearts (Ciaraldi and
Marinetti, 1977? Williams et al, 1977? Kempson et al,
1978) and increased sensitivity of myocardial adenylate
cyclase (Will-Shahab et al, 1975) and phosphorylase
activation (Hornbrook et al, 1965? McNeill and Brody,
1968; Hornbrook and Cabral, 1972) in response to
catecholamines in hyperthyroidism. Thyroid hormone
treatment also augments adenylate cyclase stimulation by a
non-hydrolysable guanosine triphosphate analogue (Will-
Shahab et al, 1975) and thus may be involved in the
regulation of the affinity state of the beta-adrenergic
receptor.
This type of experimental evidence, however, appears
contradictory to some clinical reports, discussed in
chapter 1, and does not allow the conclusion of adrenergic
hypersensitivity without more direct analysis of the
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sympathoadrenal-cardiac axis. Furthermore, rat heart
physiology differs in many important respects from that of
man and therefore extrapolation to the clinical situation
with an intact circulation may not be valid.
Propranolol has been shown to alleviate some but not
all of the clinical manifestations of hyperthyroidism
(Wilson et al, 1964; Grossman et al, 1971b; Ikram, 1977).
While, in the short term it does exert some effect on
thyroid hormone levels (see chapter 2), its major action
is mediated via the beta-adrenoceptor. The functional
effect of varying sympathetic activity can be investigated
using propranolol to antagonise sympathetic effects
mediated via the beta-adrenoceptor.
This study was designed to assess the
relative contribution of the sympathetic nervous system in
hyperthyroid patients by measuring variations in heart
rate, and the heart rate and blood pressure
responses to exercise, before and during beta-
adrenoceptor blockade. A once daily preparation of
propranolol was chosen because relatively constant plasma
propranolol concentrations had been demonstrated in
euthyroid volunteers over 24 hours following oral dosage
(McAinsh et al, 1978).
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Methods
Ten hyperthyroid patients, nine women and one
man with a mean age of 33 years (range 22-51) were
studied. The diagnosis of hyperthyroidism was made on
clinical grounds and on the basis of raised levels of
plasma total thyroxine (T4) and triiodothyronine (T3)
(table 6.1). In addition, all patients had an absent
response of plasma thyrotrophin 20 minutes after the
intravenous injection of 200 ug of thryotrophin-releasing
hormone and increased four hour uptake of iodine-132 by
the thyroid gland. Nine of the 10 patients had Graves*
disease and the tenth had a solitary autonomous
thyroid nodule. No patient had evidence of any
concurrent cardiovascular or any other disease based on
clinical examination, ECG and chest x-ray and all
remained in sinus rhythm throughout the study. Control
data were obtained from 10 age-matched normal
euthyroid subjects (three women and seven men) and eight
of these volunteers also received propranolol.
Informed consent was obtained from all patients prior
to participation in the investigations. Baseline
measurements of plasma total T4, T3 and 'reverse'T3(rT3)
were made in hyperthyroid subjects and a submaximal
exercise test performed using a bicycle ergometer
according to a standard protocol. All subjects were
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familiarised with the exercise equipment prior to the
definitive test. Work load was increased at three minute
intervals (250, 450, 600, 750 kpm/minute for females:
300, 600, 900, 1050 kpm/minute for males) to a symptomatic
limit. Chest leads V2, V4 and V5 were recorded
continuously using a Mingograf (Siemens Elema) three
channel recorder. Mean heart rate was calculated over 10
beats at the end of each minute of exercise and for five
minutes of recovery. Systolic blood pressure was
recorded by the same observer at rest and at two-minute
intervals during exercise using a mercury
sphygmomanometer. Heart rate was subsequently recorded
continuously as an out-patient over 24 hours with an
Oxford Medilog recording system using a modified lead V5
chest electrode. The light weight and portability of
these instruments allowed patients to undertake normal
activities during the recording period. Variations in
tape recorder speed were minimised by using the same
recorder for each subject over the taping periods and by
incorporation of a fixed frequency timing signal into the
recorder. Each 24 hour recording was analysed at sixty
times real speed (Pathfinder II high speed ECG analyser,
Reynolds Medical) and divided into one hour periods with
the mean heart rate for each period calculated.
The protocol was repeated in all patients and
in eight of the control subjects following administration
of a slow-release oral propranolol preparation (Inderal-
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14 T3 rl3 W E A3 (ngM)
1 382 >15.0 4.20 345 <15.0 3.07 455
2 23* 218 7.4 0.92 203 5.2 0.95 17
3 25F 262 11.6 2.14 232 8.7 1.93 116
4 27F 188 9.2 0.69 222 7J liO 55
5 27F 175 6.2 0.98 200 5.1 1.71 179
6 3QF 182 5.8 0.62 208 4.9 1.07 681
7 39F 129 4.2 0.30 145 3.3 0.68 68
8 22F 253 10.2 2.19 300 14.0 2.45 116
9 33F 204 10.2 1.75 246 10.6 1.48 54
10 51F 226 10.2 2.37 2B5 9.4 2.65 43
UH£ 6.1 Age, sex, plasta total 14, T3 and rT3 before and daring pxpanolaL
treatment and pLasia prcprsnolal levels in t^pertlryrodd patia±s.
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LA, ICI Pharmaceuticals, England) in a single daily dose
of 320 mg for six days. Blood samples for estimation
of plasma thyroid hormones and propranolol were
withdrawn six hours after the sixth dose of propranolol
and the exercise test undertaken at the same time
during the day with an identical workload to that
performed prior to beta-adrenoceptor blockade.
Subjects were asked to continue their normal daily
routines during the two taping periods.
Plasma samples were stored at -20 C for later
in-batch analysis. Plasma total T4 and T3 and rT3 were
each measured by specific radioimmunoassays (Challand et
al, 1975; Ratcliffe et al, 1976). The normal
levels ranged between 55 and 144 nmol/1 for T4, 0.9 and
2.8 nmol/1 for T3 and 0.15 and 0.42 nmol/1 for rT3.
Plasma propranolol was measured by a gas-liquid
chromatographic method (McAinsh et al, 1978).
Briefly, 1 ml of oxalated whole blood was mixed with 4-
methyl propranolol (as internal standard), mixed,
centrifuged and precipitated in sulphuric acid.
After buffering in a sodium hydroxide - chloroform/ether
solvent mixture, the drug residue -was evaporated to
complete dryness at room temperature under nitrogen.
Anhydrous diethyl ether and heptafluorobutyric anhydride
were added to the drug residue and after
evaporation to dryness under nitrogen, ethyl acetate was
added and the solution analysed using an electron capture
gas-liquid chromatographic machine (Pye GCV). The inter-
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assay coefficient of variation for the propranolol
estimation was seven per cent.
The mean percentage reduction in peak exercise heart
rate (EHR) was calculated by the following equation:
EHR (prepropranolol) -
EHR (post propranolol)
% reduction in EHR = —1 x 100
EHR (prepropranolol)
Differences in heart rate, blood pressure and thyroid
hormone levels during sympathetic blockade were assessed
by Student's t test for paired observations. A five per
cent level of confidence was considered statistically
significant. Correlations between heart rate and log
propranolol or thyroid hormone concentrations used a
linear regression coefficient with least squares method of
analysis. Data are quoted as mean +/- standard error of
the mean.
One patient (no. 6) showed frequent multifocal
ventricular extrasystoles with several periods of sinus
arrest of up to two seconds during monitoring (see figure
6.7). She was excluded from nocturnal and resting heart
rate analysis because of these abnormalities.
Results
Nyctohemeral heart rate response
Figure 6.1 (upper panel) shows the mean heart rate
during each hour of the 24 hour period of monitoring in
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the hyperthyroid and control subjects before and during
propranolol therapy. In untreated hyperthyroidism, heart
rate was relatively higher during the day (0700 - 2300
hours) than during the night (2300 - 0700 hours) (P <
0.001). This pattern of nyctohemeral variation in heart
rate was strikingly similar to that seen in the euthyroid
state. Thus, when untreated hyperthyroid patients were
compared to untreated euthyroid controls, the increase in
heart rate with hyperthyroidism during the day (27.9 +/-
1.0 beats/minute was the same as that during the night
(26.7 +/- 0.8 beats/minute). In effect, the baseline
heart rate in hyperthyroidism is increased but with no
change in the pattern of reponse over 24 hours.
Propranolol reduced the mean heart rate at all times of
the day and night, although in both hyperthyroid and
euthyroid groups the fall in heart rate was
significantly greater during the day than during the
night (P < 0.01). Propranolol decreased the overall
variation in heart rate during the 24 hour period,
leaving a relative nocturnal tachycardia in the
hyperthyroid subjects. During beta-adrenoceptor blockade,
the increase in heart rate with hyperthyroidism was
constant during the 24 hour period and hence
independent of higher (daytime) or lower (night-time)
sympathetic activity.
The percentage reduction in heart rate with
propranolol over 24 hours in the hyperthyroid and
euthyroid groups is shown in figure 6.1 (lower panel).
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FIGURE 6.1 Heart rate variation (mean +/- SEM). over 24
hours in untreated hyperthyroidism (n=9) and
euthyroid controls (n=8) before and after
six days of slow-release propranolol (upper
panel). The adrenergic component of heart
rate (percentage reduction after
propranolol) over 24 hours in hyperthyroid
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No differences are apparent between the groups either
during the day or night despite the variation in
sympathetic activity over this time, reflected in a
greater percentage reduction in heart rate during the day
(22 +/- 1% hyperthyroid: 22 +/- 1% euthyroid) than during
the night (16+/-1% hyperthyroid; 15+/-1% euthyroid).
Exercise Response
Parallel heart rate responses to exercise were also
observed in the hyperthyroid and euthyroid subjects
(figure 6.2, upper panel). The mean peak EHR was
increased from 168 +/~ 7 beats/minute in the euthyroid
subjects to 193 +/- 9 beats/minute in the
hyperthyroid subjects (p < 0.01) but this increase (25
+/- 5 beats/minute) was similar to the difference in
resting heart rate between hyperthyroid and euthyroid
individuals (32 +/- 4 beats/minute). In contrast,
propranolol therapy caused a greater fall in peak EHR
than in resting heart rate in both the hyperthyroid
and euthyroid groups. These changes are
summarised in table 6.2. Hyperthyroidism increases heart
rate equally at rest and on exercise with a blunted
response during beta-adrenoceptor blockade.
The percentage reduction in heart rate with
propranolol during exercise and recovery (figure 6.2 lower
panel) showed no major differences in hyperthyroid and
euthyroid subjects. As expected, the anti-adrenergic
effect of propranolol is increased progressively during
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FIGURE 6.2 Heart rate responses (mean +/- SEM) during
and after graded exercise on a bicycle
ergometer in untreated hyperthyroidism
(n=10) and euthyroid controls (n=8) before
and after six days of slow-release
propranolol (upper panel). The adrenergic
component of heart rate responses during
exercise and recovery (percentage reduction
after propranolol) in
hyperthyroid and euthyroid subjects is





























































TABLE 6.2 Mean (+/-SEM) fall in heart rate (beats/minute)
with propranolol therapy at rest and on peak
exercise in hyperthyroid and euthyroid groups.
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exercise, reflecting augmented overall sympathetic
activity at this time. The slope of this line during
exercise is, in effect, a dose-response curve and is a
measure of,adrenergic sensitivity. The slope on exercise
was similar in both hyperthyroid (slope = 0.85; r = 0.87)
and euthyroid (slope = 0.84; r = 0.95) groups.
The maximum rise in systolic blood pressure on
exercise was similar in the hyperthyroid subjects (43 +/-
5 mmHg) and euthyroid controls (48 +/- 6 mmHg). After
beta-adrenoceptor blockade, the reduction in systolic
blood pressure was independent of thyroid status at all
levels of exercise and recovery (figure 6.3).
Heart Rate/Thyroid Hormone Relationship
As shown in figure 6.4a and 6.4b, a highly
significant linear correlation existed between mean heart
rate between 0400 and 0600 hours and log plasma T3 and T4
during propranolol treatment in hyperthyroid patients.
Endogenous sympathetic activity would be expected to be
low during this period and with additional pharmacological
sympathetic blockade, heart rate was closely related to
circulating thyroid hormones, in particular T3. A slightly
less good correlation existed between these parameters in
hyperthyroidism in the absence of propranolol (figure 6.4c
and 6.4b) reflecting a small but variable component of
endogenous sympathetic activity in the basal heart rate at
this time.
Resting heart rate on propranolol immediately prior
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FIGURE 6.3 The redaction in systolic blood pressure
during exercise and recovery follow] Sbeta-
adrenoceptor blockade with slow-release
propranolol in hyperthyroid (n = 10) and
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FIGURE 6.4 Mean heart rate between 0400 hours and 0600
hours correlated with plasma total T3 (a)
and T4 (b) while on propranolol and plasma
total T3 (c) and T4 (d) in untreated
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FIGURE 6.5 Mean resting heart rate prior to the exercise
test correlated with plasma total T3 (a) and
T4 (b) while on propranolol and plasma total
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to the exercise test was also linearly relatedto log
plasma total T3 and T4 (figure 6.5a and 6.5b). However, a
clear linear relationship between these parameters was not
identified in the absense of propranolol (figure 6.5c and
6.5d) when it is likely that a variable sympathetic
component to heart rate obscured its dependence on thyroid
hormone concentrations.
No correlation was identified between peak EHR and
log thyroid hormone concentrations with or without
propranolol.
Heart Rate/Propranolol Relationship
Plasma propranolol concentrations measured six hours
after the sixth oral dose showed a 40-fold variation in
hyperthyroid individuals. There was no obvious
relationship between propranolol concentrations and levels
of thyroid hormones (table 6.1). Despite these
variations in plasma propranolol in the hyperthyroid
group, there was a mean percentage reduction in peak EHR
of 33 per cent with a minimum reduction in peak EHR of 25
per cent suggesting satisfactory functional beta-
adrenoceptor blockade in these subjects. In the
euthyroid controls plasma propranolol varied three-fold
from 54 to 160 ug/ml. A mean percentage reduction in peak
EHR of 32 per cent was achieved with a minimum reduction
of 26 per cent also suggesting adequate beta-adrenoceptor
blockade. The percentage reduction in peak EHR showed a
positive correlation with log plasma propranolol
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concentrations in both groups (figure 6.6). There was no
correlation between the percentage reduction in resting
heart rate and log plasma propranolol concentration in
either group (hyperthyroid r = 0.18; euthyroid r = 0.34;
P=NS).
Thyroid Hormone Levels During Propranolol Treatment
The levels of T3, T4 and rT3 before and during
propranolol treatment are detailed in table 6.1. The
mean T3 fell from 9.0 +/- 1.0 to 8.4 +/- 1.2 nmol/1
following propranolol while the mean T4 rose from 222 +/-
22 to 239 +/- 18 nmol/1 and rT3 rose from 1.62 +/- 0.37 to
1.78 +/- 0.56 nmol/1. None of these changes achieved
statistical significance.
ECG Abnormalities on Exercise
Two patients showed unequivocal ECG abnormalities
during the exercise test in the untreated hyperthyroid
state when both denied specific cardiovascular symptoms.
The first (No. 1) developed asymptomatic 2 mm horizontal
ST segment depression during exercise and for two minutes
in recovery (figure 6.7r upper panel). She had markedly
elevated plasma thyroid hormone levels (table 6.1) and
achieved a peak heart rate of 199 beats/minute after only
2 1/2 minutes exercise at 250 kpm/minute. ECG
abnormalities were not detected on exercise after
treatment with propranolol and subsequent testing when the
patient was euthyroid showed no abnormality (figure 6.7).
This patient showed a relatively large (14 per cent) fall
in left ventricular ejection fraction on exercise
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FIGURE 6.6 Percentage reduction in peak exercise heart
rate (EHR) in relationship to plasma
propranolol concentration in hyperthyroid
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(discussed in chapter 4) when hyperthyroid that contrasted
with a 23 per cent rise when subsequently euthyroid.
The second patient, a 30 year old woman (No. 6),
developed first degree heart block and achieved a heart
rate of 222 beats/minute after five minutes of exercise
when hyperthyroid on no therapy. Asymptomatic ST segment
elevation was detected in the inferior leads for two
minutes in recovery (figure 6.7, lower panel). ECG
monitoring over 24 hours showed frequent multifocal
ventricular extrasystoles with periods of sinus arrest.
Exercise testing and ECG monitoring when hyperthyroid on
propranolol and subsequently when euthyroid showed no
abnormalities.
Discussion
The hypothesis that the circulatory manifestations of
hyperthyroidism were mediated through the sympatho-
adrenal-raedullary system lost some credibility with the
demonstration of direct inotropic and chronotropic effects
of thyroid hormones on the myocardium (Symons 1979).
This has been strengthened by the knowledge that binding
sites for thyroid hormones that best fulfilled the
criteria for hormone receptors were in the cell nucleus
and not the cell membrane. (Degroot and Torresani, 1975;
Oppenheimer et al, 1976; Surks and Oppenheimer, 1977).
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FIGURE 6.7 Upper panel: ECG abnormalities on exercise in
patient no.l in the untreated hyperthyroid
state (14/6/79) and at the same heart rate
when euthyroid (31/8/79). Two mm. ST segment
depression is detected only when
hyperthyroid. Lower panel: ECG at rest (left)
and immediately after exercise (right) and
trace from daytime ECG monitoring in patient
no.6 in the untreated hyperlityroid state.
Exercise testing and ECG monitoring when
euthyroid were normal.
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T3 appears to be the physiologically important ligand with
T4 and the circulating products of T4 metabolism playing a
physiologically less active role.
An increase in beta-adrenoceptor density in
experimental hyperthyroidism does, however, imply
adrenergic hypersensitivity, i.e. an increase in target
organ response for a given adrenergic stimulus (Lefkowitz
1979), provided that such receptors remain physiologically
responsive to both neural and humoral stimuli. In vitro
studies cannot resolve this important question. This
study, therefore, has examined this relationship by
measuring nyctohemeral and exercise-induced heart rate
responses in hyperthyroid patients before and during beta-
adrenoceptor blockade with propranolol and by comparing
the results to those obtained with age-matched euthyroid
controls.
Endogenous sympathetic neural activity fluctuates
during the day, being greatest during physical exertion
and lowest during sleep. Untreated hyperthyroid patients
showed a strikingly parallel heart rate response compared
to euthyroid controls (figure 6.1). If there were any
augmentation of adrenergic sensitivity in hyperthyroidism,
a greater increase in heart rate would be expected during
the day (a time of increased sympathetic neural activity)
than during the night (when sympathetic activity is
relatively low). This did not occur. Similarly, there
was no greater heart rate or blood pressure response to
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exercise in untreated hyperthyroidism compared to
euthyroid controls. Following propranolol, the percentage
reduction in heart rate (figures 6.1 and 6.2) and systolic
blood pressure (figure 6.3) appeared to be independent of
thyroid status. In effect, dose-response curves
have been constructed relating varying sympathetic
activity (day and night; exercise) to the adrenergic
response (percentage change after beta-adrenoceptor
blockade). The similarity of the results suggests normal
adrenergic responsiveness in hyperthyroidism.
As expected, the reduction in heart rate in both
hyperthyroid and euthyroid subjects on propranolol was
greater during the day than at night. Assuming adequate
beta-adrenoceptor antagonism (vide infra) the nocturnal
heart rate in hyperthyroid patients on propranolol (when
functional adrenergic activity is lowest) can be
considered to reflect a direct chronotropic effect of
thyroid hormones independent of the sympathetic nervous
system - beta-adrenoceptor axis. It could thus be
anticipated that the closest linear correlation would
exist between plasma thyroid hormones and nocturnal heart
rate in the presence of beta-adrenoceptor blockade (figure
6.4 a,b). It is the 'free' T3 concentration that
principally determines the tissue responses, so the
relationship is closer for plasma total T3 than for plasma
total T4. With increased daytime sympathetic activity,
the relationship is less good (figure 6.5 a,b) despite
propranolol. In the absence of beta-adrenoceptor
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blockade, there is a reduced correlation at night (figure
6.4 c,d) and a further reduction during the day (figure
6.5 c,d). The similarity in daytime heart rate between
propranolol treated hyperthyroid patients and untreated
euthyroid controls simply reflects the similarity in
chronotropic response of the heart to excess circulating
thyroid hormones on one hand and normal daytime
sympathetic neural activity on the other.
As demonstrated previously, a substantial individual
variation in plasma propranolol concentration has been
shown in hyperthyroid patients (Feely et al, 1977;
Rubenfeld et al, 1979). The variability appears to be
similar for both conventional and slow-release
formulations of this drug. Despite this, slow-release
propranolol caused a satisfactory reduction in heart rate
throughout the day with no evidence of loss of heart rate
control with increasing time from the previous dose. In
addition, a reasonable reduction in peak EHR was achieved
even in patients with propranolol levels below 50-100
ng/ml, a level considered necessary for maximal beta-
adrenoceptor blockade in normal subjects (Coltart and
Shand, 1970; Zacest and Koch-Weser, 1972). The
percentage reduction in peak EHR still correlated with
plasma propranolol levels despite the variable influence
of thyroid hormones on heart rate (figure 6.6). It is
unlikely that the relative nocturnal tachycardia after
propranolol is related to inadequate beta-adrenoceptor
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blockade at this time. Plasma propranolol levels and
maximum reduction in peak exercise tachycardia are
maintained for over 30 hours following a single dose of
160 mg slow-release propranolol (McAinsh et alf 1978),
half the dose used in this study. Furthermore, the
percentage reduction in heart rate at night was the same
in the hyperthyroid and euthyroid groups. The reasons
for the variation in propranolol levels in hyperthyroidism
are not clear. Thyroid dysfunction has been shown to
alter the absorption, metabolism and elimination of
several drugs (Croxson and Ibbertson, 1975; Bell et al,
1977; Forfar et al, 1980). Although the kinetics of
propranolol may be altered in hyperthyroidism, plasma
protein binding appears to be constant (Kelly and
McDevitt, 1978). There was no obvious relationship
between propranolol levels and the severity of
hyperthyroidism as judged by the levels of plasma total T4
and T3 (table 6.1). There is no certainty, however, that
either of these measurements reflects its influence at a
cellular level.
Propranolol has been shown to produce a fall in
plasma total T3 concentrations (Wiersinga and Touber,
1977) associated with a rise in plasma total rT3
(Verhoeven et al, 1977). While the pattern of change
conformed to the expected trend in our patients, changes
were not statistically significant possibly due to the
numbers studied. It is unlikely that these minor changes
in thyroid hormone concentrations contribute to the
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haemodynamic effects of propranolol in hyperthyroidism
(Nilsson et al, 1980).
The presence of occult coronary artery disease cannot
be totally excluded in the two patients in whom ECG
abnormalities were manifest on exercise but it is likely
that hyperthyroidism was the major precipitating factor in
view of normal results after specific antithyroid therapy.
Metabolic symptomatic myocardial ischaemia with normal
coronary arteries has been suggested in hyperthyroidism
(Resnekov and Falicov, 1977), possibly related to thyroid
hormone actions on myocyte ATP production (Tse et al,
1980). This would be exacerbated in the two patients
described by pathological exercise-induced tachycardia 20-
30% greater than that achieved by the same patients when
euthyroid. Coronay artery spasm (Wei et alf 1979),
myocardial infarction (Proskey et al, 1971), ventricular
arrhythmias and heart block (Campus et al, 1975) and
sudden death (Parker and Lawson, 1973) have all been
sporadically reported in hyperthyroidism. It is of
interest that no abnormalities were detectable during
propranolol therapy in the patients in this series despite
persisting hyperthyroidism. Although some specific
thyroid hormone-sympathetic nervous system interaction
cannot be excluded, it is equally possible that the
protective effect of propranolol was mediated simply by
the reduction in exercise-induced tachycardia to more
physiological levels. It is unlikely that the minor
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changes in plasma thyroid hormone levels following
propranolol would contribute to this effect.
It has been argued that the presence of normal
sympathetic and adrenal medullary activity in
hyperthyroidism is inappropriate, and that the peripheral
effects of thyroid hormones should lead to inhibition of
central neurosympathetic outflow. Although direct data on
thyroid hormone action on central neurosympathetic
activity is lacking, small doses of thyroid hormone can
enhance the speed of recovery from depressive illness,
particularly in combination with drugs that increase the
availability of brain catecholamines (Prange et al, 1969;
Wheatley, 1972). It should be stressed, however, that
even if thyroid hormones promote transmission in central
noradrenergic pathways (Whybrow and Prange, 1981),
peripheral adrenergic hypersensitivity would not occur
unless catecholamine responses to sympathetic activation
were increased. This has not been demonstrated (see
chapter 1).
Okada et al, (1980) have recently shown that plasma
cyclic AMP responses to hypoglycaemia are potentiated in
hyperthyroidism suggesting increased beta-adrenoceptor
responsiveness, in contrast to our findings. It has been
suggested that cardiac (beta 1) adrenoceptors (mediating
changes in heart rate) are closely related to adrenergic
nerve terminals whereas peripheral (beta 2) smooth muscle
adrenoceptors may be more widely distributed and more
responsive to circulating catecholamines. It may be,
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therefore, that hyperthyroidism has a differential effect
on sub-types of beta-adrenoceptors with augmented
metabolic responses but no change in neurally mediated
cardiac responses. Indeed, the formation of cyclic AMP
and activation of cyclic AMP dependent protein kinase in
the hyperthyroid rat heart in the absence and in the
presence of isoprenaline is lower than in the euthyroid
rat heart (Tse et al, 1980).
This study suggests that sympathetic neural
sensitivity, defined in terms of heart rate and blood
pressure responses, is normal in hyperthyroidism.
Baseline heart rate is reset secondary to the levels of
circulating thyroid hormones, but the rate and magnitude
of the sympathetic response is unchanged from the
euthyroid state. Propranolol administration abolishes
the sympathetic component of the heart rate response,
unmasking a direct dose-related thyroid hormone effect.
Any increase in beta-adrenoceptor number secondary to
hyperthyroidism does not therefore seem to influence
cardiac sympathetic neural responsiveness.
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CHAPTER 7
Thyroid Hormone Action on Paracetamol Pharmacokinetics:
Implications for Rational Therapeutics in
Thyroid Disease.
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It is now well established that drug metabolism may
be substantially altered by disease. Chronic liver
disease (Blaschke, 1977), renal disease (Dettli, 1976),
pulmonary disease (Du Souich et al, 1978) and congestive
heart failure (Nies et al, 1976) can all impair different
components of drug disposition following oral or
parenteral administration. Many physiological and
autonomic changes affecting most organ systems are
associated with thyroid disease (Werner and Ingbar, 1978),
giving several different mechanisms of alteration in drug
absorption, metabolism and elimination (Eichelbaum, 1976;
Shenfield, 1981). Despite this, few studies have reported
on the effects of thyroid disease on drug disposition and
yet changes in drug handling in patients with abnormal
thyroid function may have important therapeutic
implications in the management of the cardiovascular
consequences of thyroid dysfunction. Altered gut motility
in hyperthyroidism (Shirer, 1933; Christensen et al, 1964;
Thomas et al, 1973) and hypothyroidism (Bacharach and
Evans, 1957, Wohl and Nixon, 1965; Christensen et al,
1966; Holdsworth and Besser, 1968) may influence the rate
and extent of drug absorption and therefore the speed of
onset and magnitude of drug effect. Similarly, changes
in gut mucosal function (Siurala et al, 1966; Bernstein
and Ridings, 1970), changes in regional blood flow
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(DeGroot and Leonard, 1970) or alteration in drug
metabolising enzyme activity (Kato and Takahashi, 1968;
Pitot and Yatvin, 1973) may modify drug distribution and
elimination and thereby influence the magnitude and
duration of drug effect.
This study has investigated the influence of thyroid
function on paracetamol disposition after oral
administration. Paracetamol was used because of its
safety in single dosage, ease of measurement and reported
use as a marker of drug disposition in other disease
states (Pottage et al, 1974; Nimmo, 1976; Forrest et al,
1979). It is a weak acid (pKa 9.5)that is largely
unionised in both gastric and intestinal fluids, and the
rate of absorption in man is directly related to the
gastric emptying rate (Heading et al, 1973).
Anticholinergic agents such as propantheline or narcotic
analgesics greatly increase gastric emptying time and
delay the time to reach peak paracetamol concentrations
(Nimmo et al, 1973; Nimmo et al, 1975) whereas
metoclopramide stimulates gastric emptying and increases
drug absorption in normal subjects (Nimmo, 1975).
Methods
Eighteen drug disposition profiles were obtained in
eight patients (mean age 49 years, range 35-66 years) each
studied on two or three separate occasions; seven when
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hyperthyroid, seven when euthyroid and four when
hypothyroid. Each patient therefore acted as his or her
own control. Hyperthyroidism was diagnosed clinically
and on the basis of a raised level of serum total
thyroxine (T4) or triiodothyronine (T3) or both,
associated with lack of response of serum thyrotrophin 20
minutes after the intravenous injection of 200 ug of
thyrotrophin-releasing hormone. Hypothyroidism was
confirmed by a reduced serum total T4 with raised serum
TSH, and was spontaneous in one patient, followed the
administration of therapeutic iodine 131 in two patients
and subtotal thyroidectomy in one patient. Normal thyroid
function was confirmed biochemically after treatment. A
minimum period of three months elapsed after each
treatment to allow biological adjustment to the change in
thyroid hormone levels. Serum total T3, T4 and TSH
levels were measured by specific radioimmunoassay (Irvine
et al, 1973; Seth et al, 1976) as described in chapter 2.
The laboratory reference ranges for T3 were 1.1 - 2.2
(male) or 2.6 (female) nmol/1, for T4 60-150 nmol/1 and
for TSH less than 0.7 to 5.7 mU/1.
Patient details and thyroid hormone levels, with
their respective normal ranges are shown in table 7.1.
No patient had evidence of concurrent cardiac, hepatic or
gastrointestinal disease and all drug therapy was
withdrawn 48 hours before each study. Patients 1, 4 and
8 had been on long-term thyroxine replacement therapy
(100-150 ug per day) when euthyroid: patient 2 had been
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EKUENT flfiR(VR) H5flttKliEEC!ID EDIH3CQD HVrnTHVHCnp
SfiEX WT 14 13 WT 14 131 WT 14 131
(kg) (mcO/L) (kg) (mo]/L) (ntyi) (kg) (jmcd/L) (nq/1)
1 53! 73.5 127 3.0 81.0 68 4.5 83.0 <20 40.8
2 51M 83.0 188 4.5 84.0 99 1.0 - -
3 38F 52.5 230 5.5 55.0 80 1.0 - -
4 2SF 49.5 195 5.8 55.0 107 0.8 55.5 <20 63.0
5 50M 74.0 238 6.9 85.0 89 0.9 75.0 34 55.8
6 66M 67.0 248 5.7 80.5 67 9.9 - -
7 36P 60.5 256 4.5 - - - -
8 62F - - - 72.0 92 2i 69.0 <20 96.0
UELE 7.1 flge at initial diagnosis, sex, vei^xt and levels of thyroid hormones
and serum 13! at times cf study.
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on digoxin 0.25 mg per day when hyperthyroid (although
atrial fibrillation had not been documented) and patient 6
had been on propranolol 10 mg three times per day when
hyperthyroid and a thiazide diuretic
(cyclopenthiazide/potassium chloride) when euthyroid.
After an overnight fast, paracetamol solution at room
temperature (20 mg/kg dissolved in 400 ml water) was given
orally over two minutes, and venous blood samples were
taken from an indwelling cannula at 0, 3, 6, 10, 15, 20,
25, 30, 40, 50, 60, 75, 90 and 120 minutes and 3, 4, 6 and
8 hours after drug administration. Patients continued to
fast lying supine in bed for the first two hours, but
thereafter were permitted food, fluids and normal
activity. Smoking was not permitted throughout each
study.
Plasma (3 ml) was separated, stored frozen and later
assayed in duplicate for paracetamol content using high
performance liquid chromatography according to the method
of Adriaenssens and Prescott, (1978). Briefly, aliquots of
plasma (1ml) were mixed with 100 ul internal
standard/protein precipitant solution (containing 300
ug/ml propionyl-4-amino phenol in 30 per cent aqueous
perchloric acid) and injected with a solvent flow (0.1M
potassium dihydrogen phosphate; 98% formic acid and
isopropanol [ 100:0.1:1.7v/v/v]) of 0.9 ml perminute. An
Orlita pump with a Waters model 440 UV absorbance detector
(254nm filter) were used and peak areas measured with a
Hewlett-Packard HP3370 A integrator. The columns were
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stainless steel tubes 100mm x 4.9mm packed with Hypersil-
00S (Shandon Southern Products) and fitted with a septum
injector. The chromatogram peaks for paracetamol and the
sulphate and glucuronide conjugates were distinct and
separate samples could be injected every 18 minutes. The
limit of measurement with a 5 ul injection was lug per ml.
The standard deviation of replicate assays of paracetamol
was less than 3 per cent on a concentration range of 1-250
ug per ml. Day to day reproducibility was 3 to 4 per
cent.
Drug absorption was assessed by measurement of the
peak plasma concentration achieved and the time to peak
concentration. Total body clearance was estimated from
the area under the plasma concentration-time curve
extrapolated to infinity and assuming 100 per cent
bioavailability and the half-life (Tl/2) estimated from
the terminal slope (4-8 hours).
In addition, estimates of the absorption,
distribution and elimination rate constants, and the
central and peripheral compartment volumes were obtained
by non-linear regression analysis of the plasma
concentration-time curves in terms of a two compartment
open pharmacokinetic model with first order absorption
(Gibaldi and Perrier, 1975). This model, shown
schematically in figure 7.1, adequately describes the fate
of many drugs in man and its mathematical solutions are
consistent with intuitive notions of drug behaviour in
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biological tissues (Riegelman et al, 1968; Greenblatt and
Koch-Weser, 1975 a,b).
Statistical comparisons between the groups were made
using standard parametric techniques for paired
observations (two-tailed). All data are quoted as mean
+/- SEM.
Results
Mean plasma paracetamol concentration-time curves
showed three distinct patterns in the hyperthyroid,
euthyroid and hypothyroid groups (figures 7.2 and 7.3).
The time to peak concentration was significantly shortened
in the hyperthyroid, compared to euthyroid group (14
minutes compared to 25 minutes; PCO.OOl) , and was
prolonged in the hypothyroid groups (33 minutes) although
differences did not achieve statistical significance at a
5 per cent level of confidence. The absorption half-life
was correspondingly shortened in the hyperthyroid group
with a trend for prolongation when hypothyroid (figure
7.4). In contrast, the mean peak paracetamol
concentration was lower in the hyperthyroid group (PC0.05)
than in the other two groups and there was a more rapid
whole body clearance (P<0.005) and a shorter plasma half-
life (P<0.05) in these patients (figure 7.4).
There were no significant differences between the
groups in distribution rate constants or the apparent
volume of the peripheral compartment. The overall
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FIGURE 7.1 Schematic diagram of open two-compartment





Cc AND Cp REPRESENT DRUG CONCENTRATIONS IN, AND
Vc AND Vp APPARENT VOLUMES OF CENTRAL AND PERIPHERAL
COMPARTMENTS. FIRST-ORDER RATE CONSTANTS OF DRUG
ABSORPTION (KA) AND ELIMINATION (KE) FROM THE CENTRAL
COMPARTMENT AND HYBRID DISTRIBUTION RATE CONSTANT («D)
BETWEEN CENTRAL AND PERIPHERAL COMPARTMENTS ARE
INDICATED.
FIGURE 7.2 Plasma paracetamol concentration (mean +/-
SEM) time curves in hyperthyroid, euthyroid
and hypothyroid patients over the first




FIGURE 7.3 Plasma paracetamol concentration - time
curves in hyperthyroid, euthyroid and
hypothyroid patients over 1-8 hours after



























apparent volume of distribution, however, was largest in
the hyperthyroid group, but the differences were not
significant. This trend was due to differences in the
volume of the central compartment, which was significantly
greater in the hyperthyroid group than in the other two
(PC0.025). A summary of those pharmacokinetic variables
is shown in table 7.2.
Discussion
Despite the profound effects of altered thyroid
activity on the function of many organs, few attempts have
been made to investigate the influence of thyroid disease
on drug disposition. In general, most of the changes
would tend to increase plasma and tissue drug
concentrations in hypothyroidism and lower them in
hyperthyroidism. Drug effects may be further modified by
thyroid hormone induced changes in target organ
responsiveness, for example altered drug-receptor binding
or cellular enzymic activity may substantially modify drug
efficacy.
Drug absorption may be accelerated by the increase in
gut motility in hyperthyroidism, as demonstrated in this
investigation using a drug whose absorption is dependent
on the rate of gastric emptying (Nimmo, 1976).
Conversely, drug absorption may be slowed by the
hypomotility associated with thyroid hormone deficiency.
The site of absorption, however, is a major determinant of
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FIGURE 7.4 Time to peak concentration, peak
paracetamol concentration and
half life (upper panel) and total body
clearance and plasma half-life in
hyperthyroid (T), euthyroid (E) and












































































PARAMETER HYPERTHYROID EUTHYROID HYPOTHYROID
Max cone 28.3 +/-1.5 34.9 +/-2.3 36.6 +/-4.3
(ug/ml)
Time to peak cone 13.6 +/-1.8 25.0 +/-1.9 33.8 +/-6.9
(min)
Ka (min"1) 0.13 +/-0.03 o.08 +/-0.01 0.07 +/-0.02
Kq (min"1) 0.050 +/-0.003 0.054 +/-0.002 0.050 +/-0.003
Ke (min"1) 0.006 +/-0.001 0.005 +/-0.001 0.004 +/-0.001
T1/2 (min) 122-5 +/" 10.5 143.4 +/" 8.7 166.4 +/-18.4
TBC (ml/min/g) 5.4 +/-0.3 4.1 +/-0.2 3.6 +/-0.6
TOTAL VD (1/g) 0.94 +/-0.06 0.83 +/-0.04 0.81 +/-0.07
Vc (1/g) 0.50 +/-0.02 0.41 +/-0.03 0.38 +/-0.04
Vp (1/g) °-45 +/-0.07 0.43 +/-0.03 0.43 +/-0.05
L, Kq, Ke : absorption, distribution and elimination rate constants.T*: plasma half-life. TBC: total body clearance. V VC VP!
volumes of distribution of total, central and peripheral compartments.
TABLE 7.2 Pharmacokinetic parameters derived from computer analysis
of plasma paracetamol concentration - time curves using
a two compartment open model with first order input.
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the effect of changes in gastrointestinal transit time.
Riboflavin, for example, is absorbed by a specialised,
saturable transport system in the small intestine and the
extent of absorption is a function of its duration of
contact with the absorptive sites (Levy and Jusko, 1966).
Prolongation of intestinal transit time using an
anticholinergic drug thus increased riboflavine absorption
(Levy et al, 1972a) and, since it was not metabolised,
urinary excretion was similarly enhanced (Jusko et al,
1970). Levy et al, (1972b) have also investigated
riboflavine absorption in children with thyroid disease
and shown that urinary excretion (and hence drug
absorption) was highest in the hypothyroid (16% of dose)
and lowest in the hyperthyroid (4% of dose) groups.
Values in both groups were similar when euthyroid (8% of
dose). Urinary excretion of riboflavine was not
influenced by thyroid status after intramuscular
administration suggesting that intestinal transit time was
the factor accounting for the differences.
In this study, paracetamol concentrations peaked
earlier and tended to decline more rapidly in hyperthyroid
than in euthyroid patients, and the same pattern was
observed when euthyroid patient,s were compared to those
with hypothyroidism. No single factor appeared to be the
major cause of these differences. A reduced time to
peak concentration can be due either to accelerated
absorption or accelerated distribution and elimination,
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and in this study both absorption and elimination rate
constants were greater in hyperthyroid than in euthyroid
patients and to a lesser extent in euthyroid than in
hypothyroid patients. The combination of an increase in
both absorption and elimination may have been sufficient
to produce the large reduction in time to peak drug
concentration seen in the hyperthyroid group.
Drug elimination may be accelerated in
hyperthyroidism and slowed in hypothyroidism. Antipyrine
metabolism has been used as an index of hepatic microsomal
enzyme function in several studies. In all of these,
changes in the volumes of distribution with differing
thyroid function were minimal, whereas plasma clearance
was significantly enhanced in hyperthyroidism (Crooks et
al, 1973; Eichelbaum et al, 1974; Vessell et al, 1975)
and decreased in hypothyroidism (Vesell et al, 1975).
The alteration in clearance is probably due to changes in
hepatic metabolism and this is supported by the studies of
Eichelbaum et al, (1973) who showed that urinary excretion
of the hepatic metabolite 4-hydroxyantipyrine was
decreased in hypothyroid patients and returned to normal
as the patients became euthyroid. Experimentally,
thyroid hormones influenced mixed function oxidase enzyme
activity in liver microsomes, although results varied with
the substrate used and the sex of the animal (Conney and
Garren, 1961; Kato and Takahashi, 1968). Enhanced drug
elimination in hyperthyroidism and reduced elimination in
hypothyroidism has been shown for Cortisol (Peterson,
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1958; Linquette et al, 1975) and for methimazole (Balzer
et alf 1975; Vessel et al, 1975) although inconsistencies
remain (Skellern et al, 1980). The half-life of
thyroxine and T3 themselves is similarly affected (Gilman
and Murad, 1975; Bianchi et al, 1977). The increase in
paracetamol elimination demonstrated here is in keeping
with the known effect of thyroxine on drug metabolising
enzyme activity.
In contrast, the metabolism of testosterone was
increased in hypothyroidism with increased conversion to
androstenenedione and reduced levels of plasma
testosterone (Gordon et al, 1969). The reverse occurred
in hyperthyroidism and after treatment, values returned to
normal. These differences cannot be explained on the
basis of enzyme induction but may be secondary to changes
in sex hormone binding globulin production. Hepatic
production of this protein is enhanced in hyperthyroidism
(Vermeulen and Verndonck, 1972) and levels of oestrogen,
testosterone and the protein return towards normal after
antithyroid therapy (Akande and Anderson, 1975).
The significant reduction in peak paracetamol
concentration in the hyperthyroid group merits further
consideration. Accelerated absorption produces early
peaks of increased magnitude whereas accelerated
elimination produces early peaks of decreased magnitude.
The effects of enhanced elimination on peak concentration
would therefore be mitigated by increased absorption in
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these patients. An explanation of the reduced peak
concentration is provided by the increase in the apparent
volume of the central compartment in hyperthyroidism,
which would tend to reduce early plasma concentrations.
However, the central compartment volume (and the total
body clearance to which it is directly related) was
calculated assuming that absorption was complete and
systemic availability 100% in all groups. It is likely
that the systemic availability of oral paracetamol is less
than complete (Rawlins et al, 1977; Perucca and Richens,
1979). Further, if systemic availability changed with
differing thyroid function by altered 'first-pass1
elimination, then the changes in distribution volume may
be more apparent than real. Such changes in systemic
availability would be consistent with the observed effects
of thyroid function on paracetamol elimination,
particularly as the effects of increased hepatic clearance
would be greater during absorption than in the post-
absorption phase because the total drug dose is initially
presented to the liver. Resolution of these alternatives
is not possible with the present data.
Alterations in pre-systemic clearance (the 'first
pass' effect) may be of considerable importance in
determining the efficacy of beta-adrenoceptor antagonists
in patients with thyroid disease. Several authors have
noted variable plasma propranolol concentrations in
hyperthyroid subjects (Rubenfeld et al, 1979; Feely et
al, 1980; Forfar et al, 1982) after oral administration.
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Most studies, however, have failed to show a significant
change in the serum half-life of propranolol with
differing thyroid status (Bell et al, 1977; Riddell et al,
1979; Riddell et al, 1980; Aro et al, 1982). Since
propranolol has a significant pre-systemic hepatic
clearance (Johnsson and Regardh, 1976 ) which is flow
dependent (Branch et al,1973), alteration in hepatic blood
flow could theoretically alter propranolol kinetics. In
support of this premis, Aro et al, (1982) observed a
significant reduction in the bioavailability of
propranolol during hyperthyroidism, while the
pharmacokinetics of sotalol were unaffected. Hallengren
et al, (1982) also noted reductions in the area under the
drug concentration-time curve in hyperthyroidism after
oral propranolol and metoprolol but no change after
atenolol or methimazole. Sotalol and atenolol have a low
hepatic extraction ratio and the major route of
elimination is excretion via the kidney. It is thus
possible that the influence of hyperthyroidism on drug
oxidation becomes apparent mainly for drugs with a high
hepatic extraction ratio that are subject to extensive
presystemic clearance.
The coumarin group of oral anticoagulant drugs are
metabolised in the liver and one might anticipate the need
for increased dosage in hyperthyroidism and reduced dosage
in hypothyroidism. However, clinical evidence suggests
that thyroid hormones potentiate the anticoagulant effect
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of warfarin (Solomon and Schrogie, 1967) and that this
effect occurs at doses which have no effect on the rate of
metabolism of the drug (Schrogie and Solomon, 1967). It
has been suggested by these authors that warfarin binding
to its receptor may be increased by thyroid hormones, but
it seems more likely that the prolongation of prothrombin
time in hyperthyroidism and the reduction in
hypothyroidism is due to altered catabolism of the vitamin
K dependent clotting factors. Thyroxine increased the
rate of degradation of factor II by 40 per cent and its
biological half-life fell from 28 to 21 hours (Weintraub
et al 1973). Hyperthyroidism shortened the biological
half-life of factors II, VII, IX and X with reciprocal
changes in hypothyroidism. This explains the need for a
reduced dose of anticoagulants in hyperthyroidism (Self, et
al 1975; Vagenakis et al 1972).
The digitalis glycosides remain the primary agent for
control of the ventricular rate in hyperthyroid atrial
fibrillation although several factors complicate their
use. Clinically, it has been known for many years that
hyperthyroid patients appear resistant to glycosides
whereas hypothyroid patients are more sensitive to the
actions of these drugs (Boas 1931; Frye and Braunwald,
1961). Experimentally, hyperthyroidism reduces the
enhancement of myocardial contractility and the
prolongation of atrioventricular refractory period after
ouabain (Morrow et al, 1963). Until more recent studies,
it was believed that these alterations were entirely
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pharmacodynamic in nature and reflected thyroid hormone
induced changes in myocardial function. In 1966,
however, Doherty and Rerkuis investigated 3H-digoxin
kinetics after intravenous injection and observed that
plasma concentrations were lower than control in the
hyperthyroid group and higher than control in the
hypothyroid group, a finding since confirmed by several
investigators using both oral and intravenous routes of
administration (Croxson and Ibbertson 1975; Shenfield et
al 1977; Bonelli et al 1978). Several reasons for these
differences are available. Changes in renal blood flow
(Bradley et al, 1974) and glomerular filtration rate
modify renal digoxin clearance (Lawrence et al 1977), an
explanation favoured by Eichenbusch et al (1970), Croxson
and Ibbertson (1975), Gilfrish (1976) and Bonelli et al
1978. However, increased hepatic metabolism (Varcedi and
Foldes, 1976; Huffman et al 1978), reduced
bioavailability (Watters and Tomkin 1975), or more likely
a combination of these factors (as shown for paracetamol)
contribute to important pharmacokinetic differences with
thyroid dysfunction. Furthermore, the kinetics of digoxin
binding to the myocardium are altered in hyperthyroidism
(Veroni and Shenfield 1980 a,b) giving increased glycoside
accumulation. It is probable that binding is to the
specific glycoside receptor Na+/K+ ATPase (Kushinsky et al
1967), which is increased in both cardiac and skeletal
muscle in hyperthyroid animals (Curfmann et al 1977;
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Sharma and Banerjee 1978b). Thus part of the apparent
digoxin resistance in hyperthyroidism must reflect a
primary effect of thyroid hormone on the heart.
The magnitude of the changes in paracetamol
pharmacokinetics in thyroid disease highlights the
importance of altered drug handling in disease. This can
have important practical consequences and although the
changes demonstrated are clearly not applicable to all
drugs, certain therapeutic guidelines may be appropriate.
Despite the widespread use of oral propranolol for
symptomatic relief in hyperthyroidism and for the
preparation of patients for thyroidectomy (Michie et al
1974; Toft et al 1978), therapeutic failures with this
drug are well documented (Ljunggren and Persson, 1975;
Eriksson et al 1977). It is likely that a major
component of these failures results from inadequate dosage
secondary to increased pre-systemic clearance of the drug.
Beta-adrenoceptor blocking drugs with a low hepatic
extraction ratio such as sotalol (Aro et al, 1982)
atenolol (McDevitt and Nelson, 1978) or nadolol are likely
to give more reproducible plasma levels in thyroid disease
and to show less variability in pharmacokinetics after
oral administration, as shown recently for sotalol (Aro et
al 1980). Indeed, sotalol has specific therapeutic
actions, namely prolongation of the cardiac action
potential (Edwardsson et al, 1980),that may make it the
beta-adrenoceptor blocking drug of choice in
hyperthyroidism particularly if associated with atrial
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fibrillation. It does not influence peripheral thyroid
hormone metabolism (Wahlberg and Carlsson, 1978). The
resting pulse rate is a poor guide to adequacy of beta-
adrenoceptor blocking drug therapy which requires
assessment of plasma concentration usually coupled with
assessment of the per cent inhibition of exercise-induced
tachycardia. Oral anticoagulant therapy in
hyperthyroidism requires particular care to avoid
excessive prolongation of the prothrombin time.
Digitalisation remajns as much an art as a science although
measurement of plasma levels should provide a guideline
for individual adjustments of dose. As with all
therapeutic agents, knowledge of pharmacokinetic and
pharmacodynamic profiles allows a more rational approach





Many of the most important consequences of thyroid dysfunction
affect the heart and circulation. Although the mode of action of
thyroid hormones is incompletely understood, physiological and
biochemical research from several investigations suggests that direct
thyroid hormone effects on the heart and interactions with the
neurosympathetic axis are of importance. Hie extent to which thyroid
hormone excess or deficiency may alter cardiac autonomic control is
discussed in addition to the pathophysiological consequences of thyroid
disease for the circulation.
Serum total thyroxine, triiodothyronine and the thyrotrophin
response to thyrotrophin-releasing hormone were measured in ninety
consecutive patients presenting to a cardiology clinic with atrial
fibrillation that could not be satisfactorily explained on the basis of
known cardiovascular disease. The arrhythmia was considered to be
"idiopathic" in sixty five patients and an unexpected development in
the natural history of an established cardiac disease in twenty five
patients. A lack of response of thyrotrophin to thyrotrophin-releasing
hormone, indicative of hyperthyroidism, was documented in twelve of the
ninety patients ( 13 percent), including three with associated heart
disease, only eight of whom had thyroid hormone concentrations outwith
the laboratory reference range. In seven of these eight patients
(predominently male), stable sinus rhythm was reestablished after
antithyroid therapy. In four patients thyroid hormone levels were
normal, probably due to the effects of concurrent illness or drug
a
therapy on peripheral thyroid hormone metabolism, and initial
cardioversion failed to establish sinus rhythm in three of these
patients. Following specific antithyroid therapy to lower thyroid
hormone levels sufficient to allow a normal thyrotrophin response to
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thyrotrophin-releasing hormone, sinus rhythm was reestablished in all
four patients, one spontaneously and three after cardioversion.
Clinically occult hyperthyroidism can be identified consistently only
with the thyrotrophin-releasing hormone test and is a treatable cause
of "idiopathic" atrial fibrillation in a significant proportion of
patients. In the presence of atrial fibrillation, an absent
thyrotrophin response to thyrotrophin-releasing hormone should be
considered sufficient grounds for antithyroid therapy even if
peripheral thyroid hormone concentrations are within the expected
normal range.
The effects of oral thyroxine in a dose sufficient to
substantially inhibit the thyrotrophin response to thyrotrophin-
releasing hormone without increasing plasma total thyroxine and
triiodothyronine outwith the normal range were investigated in seven
normal subjects. After three weeks of therapy, significant (PC0.01)
increases in night-time (7.1 +/- 0.7 beats/minute) and daytime (3.1 +/-
0.6 beats/minute) mean and minimum hourly heart rates were observed
compared to the same subjects off thyroxine. Increases were
consistently greater at night. In addition, increases in night-time
urinary flow and sodium excretion and reductions in daytime urinary
flow and sodium excretion occured such that the dayrnight ratio of
urinary flow and sodium excretion fell from 2.2 +/- 0.3 and 2.4 +/~ 0.2
respectively off thyroxine to 1.4 +/- 0.2 and 1.6 +/- 0.2 during
thyroxine (PC0.01). These results sugest that biologically significant
changes in target organ function occur with minor increases in thyroid
hormone concentrations within the normal range and that this state of
subclinical hyperthyroidism is only subclinical in as much as the
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physician is unable to detect the changes in target organ function that
develop. Hyperthyroidism is therefore a graded phenomenon and may be
characterised in its early stages by thyroid hormone concentrations
still within the normal range but recognised by the pituitary, heart,
kidney and presumably other organs as abnormal. Reassessment of the
threshold for antithyroid therapy is indicated in all patients with
isolated suppression of the pituitary-thyroid axis.
Left ventricular contractile function at rest and responses to
dynamic exercises have been examined in nine hyperthyroid and eight
hypothyroid patients before and after specific corrective therapy.
Isotope ventriculography using gated blood-pool imaging (technetium 99m
labelled HSA) was performed supine before and after propranolol
0J.5mgAg intravenously. The same protocol at the same exercise work
loads was used for each patient at restudy when euthyroid.
Hyperthyroidism was characterised by a high resting left ventricular
ejection fraction ([LVEF] 0.58+/-0.03 compared to 0.53+/-0.02
euthyroid; PC0.01) but paradoxically by a significant exercise-induced
fall in LVEF (0.55+/-0.02; PC0.01 compared to resting LVEF). In
contrast, LVEF increased on exercise when euthyroid (exercise LVEF
0.61+/-0.03; p<0.01 compared to resting LVEF) to a level significantly
greater than when hyperthyroid (P<0.02). Resting LVEF was reduced in
the hypothyroid patients (0.46+/-0-02 compared to 0.53+/-0.02
euthyroid) but the increase in LVEF with exercise was similar in both
hypothyroid and euthyroid groups. Resting LVEF in the euthyroid groups
was similar and independent of initial thyroid status. Pretreatment
with intravenous propranolol caused a similar reduction in resting LVEF
in hyperthyroid, euthyroid and hypothyroid groups. Propranolol
attenuated the rise in LVEF with exercise when euthyroid but did not
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influence the rise when hypothyroid or the fall when hyperthyroid.
Directional changes in a second index of myocardial contractile
al
function based on the shape of the volume curve during systole parcelled
the LVEF data. LVEF showed a positive correlation with heart rate for
all subjects except the hyperthyroid patients on exercise where LVEF
was unexpectedly low for heart rate both before and after propranolol.
These results suggest that intrinsic myocardial contractile function
may be depressed in both hyper- and hypothyroidism, manifest in the
former by exercise-induced reductions in myocardial contractility and
in the latter by reductions both at rest and on exercise.
As part of the further study of myocardial contractile responses
under stress in hyperthyroidism, sequential studies of systolic time
intervals, left ventricular dimensions and the derived indices of
isovolumetric and ejection phase indices of myocardial contractility
were undertaken in fifteen hyperthyroid patients at rest and during
isometric exercise before and after autonomic blockade. In addition,
nine patients were studied on up to six occasions each during
antithyroid therapy. As noted previously, hyperthyroidism at rest was
characterised by a shortened preejection period index (PEPI 111+/-
4msecs; predicted PEPI 130msecs) and total duration of
electromechanical systole (QS2I 522+/-14msecs; predicted QS2I549msecs)
but little change in left ventricular ejection time index (LVETI 413+/-
Smsecs; predicted LVETI 418msecs). A small increase in PEPI was noted
following autonomic blockade. Mean velocity of circumferential fibre
shortening (Vcf) was increased in hyperthyroid patients at rest (1.4+/-
0J.0circ/sec compared to 0.90+/-0.10circ/sec euthyroid; PC0.01) from a
combination of increased end-diastolic and reduced end-systolic
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diameter in hyperthyroidism. During isometric exercise, however, PEPI
increased substantially to 144+/~4msecs (P<0.005), and was longer thai?
that predicted from regression equations from normal subjects during
isometric exercise. Mean Vcf decreased 30 per cent on exercise when
hyperthyroid to 1.01+/~0.09circ/sec. Directional changes in these
parameters were similar after autonomic blockade. In contrast, both
PEPI and Vcf were unchanged during the same isometric exercise in these
patients after a stable euthyroid state had been achieved for at least
three months. Hie increase in PEPI and the fall in Vcf on exercise were
directly related to levels of thyroid hormones. Comparison between
these responses on exercise and thyroid status during antithyroid
therapy showed that a biochemical euthyroid state could be achieved
many weeks before normalisation of contractile responses to exercise.
It is hypothesised that left ventricular function is reversibly
depressed in hyperthyroidism evidenced by abnormalities in
isovolumetric and ejection phase indices of contractile activity during
static and dynamic exercise that return to normal only after a stable
euthyroid state has been achieved for at least three months. The
apparent changes in contractility at rest primarily reflect peripheral
effects of thyroid hormones. Autonomic blockade causes similar
reductions in myocardial contractile function in the hyperthyroid and
euthyroid state without influencing directional responses to exercise.
The relationship between the sympathetic nervous system and
cardiovascular responses has been studied in ten hyperthyroid patients
and age-matched euthyroid controls by measuring nyctoheraeral variations
in heart rate and heart rate and blood pressure responses to exercise
before and after beta-adrenoceptor blockade with slow-release
propranolol. Both groups showed a parallel variation in heart rate
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over 24 hours, with an increase in heart rate in the hyperthyroid group
that was similar during the day (28 +/-1 beats/minute) and during the
night (27 +/-1 beats/minute). Similarly, the increase in resting heart
rate (32 +/-A beats/minute) in the hyperthyroid group was close to the
increase in peak-exercise induced heart rate (25 +/-5 beats/minute).
Adequate beta-adrenoceptor blockade was achieved in all subjects as
evidenced by a percentage reduction in peak exercise heart rate of 25-
45 percent. Propranolol caused a greater reduction in day-time than
night-time heart rate in both groups and blunted the response to
exercise. Following beta-adrenocepter blockade, the mean percentage
reduction in heart rate and systolic blood pressure during exercise and
heart rate responses over twenty four hours were similar in
hyperthyroid and euthyroid groups. The shape of the adrenergic
component of heart rate responses during exercise and recovery was
independent of thyroid status. The closest correlation between thyroid
hormone levels and heart rate was that of plasma total triiodothyronine
and nocturnal heart rate during beta-adrenocepter blockade (r=0.92?
P<0.001). Excess circulating thyroid hormones therefore exert a direct
effect on the cardiovascular system additive to the sympathetic nervous
system. There is no evidence of adrenergic hypersensitivity in
hyperthyroidism.
The effects of thyroid disease on systemic autonomic activity have
been examined by analysis of the absorption, distribution and
elimination of oral paracetamol before and after treatment of
hyperthyroidism (7 patients) and hypothyroidism (4 patients) according
to an open two compartment pharmacokinetic model with first order
absorption. Absorption was faster in patients with untreated
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hyperthyroidism than when subsequently euthyroid. The peak paracetamol
concentration, however, was lower in hyperthyroid patients due to an
apparent increase in the total body clearance and a shorter plasma
half-life. Both absorption and elimination rates were reduced in
hyperthyroid patients but they were not significantly different from
the euthyroid results. The total volume of distribution and the hybrid
distribution rate constants were unrelated to thyroid status, but the
apparent volume of the central compartment was significantly greater in
the hyperthyroid group. These changes in drug handling highlight the
extent of alteration in systemic autonomic function in thyroid disease
and have important implications for rational drug prescribing in both
hyper- and hypothyroidism.
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